(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/035902 A1

(51) International Patent Classification:
A61K 31/445 (2006.01) *A61P 25/00* (2006.01)
C07D 471/10 (2006.01)

(21) International Application Number:
PCT/US2021/045446

(22) International Filing Date:
10 August 2021 (10.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/064,262 11 August 2020 (11.08.2020) US

(71) Applicant: **BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY** [US/US]; 450 Administration Building, East Lansing, Michigan 48824-1046 (US).

(72) Inventors: **TEPE, Jetze J.**; 5911 Coventry Circle, East Lansing, Michigan 48823 (US). **FIOLEK, Taylor J.**; 14020 Turner Road, DeWitt, Michigan 48820 (US). **KEEL, Katarina**; 3312 S.Deerfield Avenue, Lansing, Michigan 48911 (US).

(74) Agent: **PERDOK, Monique M.** et al.; Schwegman Lundberg & Woessner, P.A., P.O. Box 2938, Minneapolis, Minnesota 55402 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: PROTEASOME ENHANCERS AND USES THEREOF



FIG. 1A

(57) Abstract: Described herein are fluspirilene derivatives, methods for making such compounds, and the use of such compounds in the treatment of cancer, an inflammatory disease or condition or neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS.

WO 2022/035902 A1

PROTEASOME ENHANCERS AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Appl. Ser. No. 63/064,262, filed August 11, 2020, the entirety of which is incorporated by reference as if fully set forth herein.

STATEMENT OF GOVERNMENT SUPPORT

[0002] This invention was made with government support under NS111347, AG061306 and GM092715 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND

[0003] The regulation of protein synthesis, degradation, folding, trafficking and aggregation within a cell are collectively known as proteostasis. Proteostasis is maintained by a wide array of cellular machinery that work to ensure that proteins are present in the proper location, amounts and form to perform their respective functions. When one of the pathways involved with proteostasis becomes dysregulated there can be disastrous effects on the cell and even on neighboring cells. One increasingly prevalent example of this is seen in neurodegenerative diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). In these neurodegenerative diseases, accumulation of specific aggregation-prone proteins (hereafter referred to as intrinsically disordered proteins (IDPs)) leads to toxic signaling and disruption of proteostasis caused by their uncontrolled aggregation and oligomerization (hereafter, aggregation and oligomerization are used interchangeably). For example, the IDP α-synuclein (α-syn) and its oligomers are associated with the pathogenesis of PD. IDPs are named for their lack of tertiary structure allowing them to adopt numerous conformations and interact with multiple binding partners. IDPs are generally short-lived signaling proteins or transcription factors that are highly bound to other cellular components keeping free cytosolic levels low. Additionally, unbound IDPs are readily degraded by the 20S proteasome, the default protease responsible for IDP digestion. The accumulation of IDPs seen in neurodegenerative diseases can begin as a result of one of several disruptions (e.g. mutations, changes in expression, oxidative stress, aging, proteasome impairment, etc.) to their normal regulation. While α-syn may not be the sole cause of PD, there is strong evidence supporting its key role in the disease, including familial forms of PD resulting from mutations in the SNCA gene. Elevated monomeric α-syn levels are also known

to cause apoptosis-inducing aggregation in neurons. Additionally, oligomeric forms of α-syn and other IDPs have recently been shown to directly inhibit the proteasome, further disrupting its ability to regulate IDPs concentrations. These data collectively suggest that the accumulation of α-syn and formation of oligomeric species of the IDP play a critical role in the progression of PD. Due to a lack of defined binding pockets, IDPs such as α-syn, and their aggregation are difficult to target through traditional small molecule drug design. There are currently no effective treatments to hinder the progression of neurodegenerative diseases that are associated with IDP accumulation.

BRIEF DESCRIPTION OF THE FIGURES

[0004] The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed herein.

[0005] FIG. 1A is a plot showing the rate of proteolysis of fluorogenic peptide substrates by purified 20S and 26S proteasome in the presence of a concentration response (0–80 μM) of fluspirilene. These data were collected in triplicate. Error bars denote standard deviation.

[0006] FIG. 1B is a table showing the calculated AC_{200} and max fold increases in activity over the vehicle control (n=3). These data were collected in triplicate. Shown with calculated standard deviations.

[0007] FIG. 2A is a cartoon of the preferred docking site of acyl-fluspirilene (16), utilizing AutoDock Vina, in the α2-3 intersubunit binding pocket of the 20S proteasome's α-ring.

[0008] FIG. 2B a zoomed in image of compound 16 docked in the α2-3 intersubunit binding pocket.

[0009] FIG. 3 is a plot showing the rate of proteolysis of fluorogenic peptide substrates by purified 20S proteasome in the presence of a concentration response (0–80 μM) of fluspirilene analogues. These data were collected in triplicate. Error bars denote standard deviation.

[0010] FIGS. 4A-4D is a cartoon of binding models of fluspirilene and three analogues, viewed utilizing BIOVIA Discovery Studio 2020: fluspirilene (FIG. 4A), compound 16 (FIG. 4B), compound 11 (FIG. 4C), compound 20 (FIG. 4D).

[0011] FIG. 5A is a plot showing extended fluorogenic peptide analysis of N-acylated fluspirilene.

[0012] FIG. 5B is a table showing the calculated AC_{200} and max fold increases in activity over the vehicle control (n=3). These data were collected in triplicate. Shown with calculated standard deviations.

[0013] FIGS. 6A is a representative silver stain illustrating fluspirilene's enhancement of α-synuclein digestion by the 20S at 1, 3, and 10 μM.

[0014] FIG. 6B is a bar graph showing the quantification of α-synuclein digestions with fluspirilene (n=3).

[0015] FIG. 6C is a bar graph showing the quantification of α-synuclein digestions with N-acylated fluspirilene (16) (n=5). Error bars denote standard deviation. Ordinary one-way ANOVA statistical analysis was used to determine statistical significance (ns=not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

[0016] FIG. 7A is a bar graph showing 20S Proteasome activity impaired by α-syn mixed aggregates in the presence of a concentration-gradient of fluspirilene. FIGS. 7A-7H show proteasome activity assay: Prevention of α-synuclein and amyloid beta (Abeta) oligomer-induced impairment of 20S proteasome activity towards fluorogenic peptide substrates by fluspirilene and N-acyl fluspirilene. White bar = 20S + vehicle. Black bars = 20S + IDP oligomer (α-syn or Abeta) + compounds.

[0017] FIG. 7B is a bar graph showing 20S Proteasome activity impaired by α-syn mixed aggregates in the presence of a concentration-gradient of N-acylated fluspirilene.

[0018] FIG. 7C is a bar graph showing 20S Proteasome activity impaired by amyloid beta mixed aggregates in the presence of a concentration-gradient of fluspirilene.

[0019] FIG. 7D is a bar graph showing 20S Proteasome activity impaired by amyloid beta mixed aggregates in the presence of a concentration-gradient of N-acylated fluspirilene. These data were collected in triplicate (n=3). Error bars denote standard deviation. One-way ANOVA statistical analysis was used to determine statistical significance.

[0020] FIG. 7E is a representative western blot analysis of α-synuclein oligomer digestion with fluspirilene.

[0021] FIG. 7F is a bar graph showing the quantification of remaining oligomeric α-synuclein. These data were collected in triplicate (n=3).

[0022] FIG. 7G is a representative western blot analysis of α-synuclein oligomer digestion with N-acylated fluspirilene.

[0023] FIG. 7H is a bar graph showing the quantification of remaining oligomeric α-synuclein (n=4). Error bars denote standard deviation. One-way ANOVA statistical analysis was used to determine statistical significance (ns=not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

[0024] FIG. 8 shows fluspirilene and N-acylated fluspirilene (16) enhanced proteasomal degradation of cellular A53T α-synuclein in transiently transfected HEK-293T cells.

SUMMARY

[0025] The disclosure relates to small molecules that enhance proteasome function and restore the activity of impaired proteasomes. Small molecule proteasome enhancers prevent the toxic accumulation of aggregation-prone proteins and prevent neuronal cell death caused by aggregation-prone proteins. The disclosure therefore relates to the use of small molecules as therapeutic agents to treat neurodegenerative diseases. Neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD-related disorders, Prion disease, Motor neuron diseases (MND), Huntington's disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA).

DESCRIPTION

[0026] Currently, there are no available therapeutics to prevent or slow down the progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's. The disclosure relates to a chemotype that has been shown herein to be a biologically active enhancer of mammalian proteasomes. The chemotype described herein is based on fluspirilene and derivatives thereof.

[0027] The disclosure relates to fluspirilene and derivates thereof, and their use to, among other things, prevent or slow down the progression of neurodegenerative diseases. The disclosure therefore relates to compounds of the formula (I)



(I)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:

R^1 is alkyl, alkenyl, cycloalkyl, aryl or heteroaryl; and

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl.

[0028] An example of a compound of formula (I) is a compound of the formula (Ia):



(Ia)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:

R^3 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester; and

R^4 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester;

X^1 is alkyl or alkenyl;

X^2 is N or CR^5, wherein R^5 is absent (e.g., when X^1 is alkenyl), hydrogen, alkyl or aryl.

[0029] Another example of a compound of formula (I) is a compound of the formula (Ib):



(Ib)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[0030] Yet another example of a compound of formula (I) are compounds of the formulae (Ic) and (Id):



(Ic)

and



(Id)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

n is 0, 1 or 2.

[0031] Yet another example of a compound of formula (I) are compounds of the formulae (Ie) and (If):



and



(Ie) (If)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

q is 0, 1 or 2.

[0032] Yet another example of a compound of formula (I) is a compound of the formula (Ig):



(Ig)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl;

each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl (e.g., R^7-C=O or R^8-C=O, wherein R^8 is halo);

X^1 is alkyl (e.g., $-(CH_2)_n-$), wherein n is 0, 1, or 2, or alkenyl; and

X^2 is N or CR^5, wherein R^5 is absent (e.g., when X^1 is alkenyl), hydrogen, alkyl or aryl.

[0033] Yet another example of a compound of the formula (I) is a compound of the formulae (Ih) and (Ii):



(Ih)



(Ii)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

n is 0, 1 or 2;

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl; and

each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl (e.g., R^7-C=O or R^8-C=O, wherein R^8 is halo).

[0034] In the compounds of the formulae (I) and (Ia)-(Ii), the alkyl, alkenyl, cycloalkyl, aryl, and heteroaryl groups of R^1 can be unsubstituted or substituted as described herein. For example, when the alkyl, cycloalkyl, aryl, and heteroaryl groups of R^1 are substituted, they can be substituted with halo (e.g., Cl, Br, and F), amino, OR^6, wherein R^6 is hydrogen, alkyl, aryl or arylalkyl, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.

[0035] In the compounds of the formulae (I) and (Ia)-(Ii), the alkyl, cycloalkyl, aryl, and heteroaryl groups of R^2 can be unsubstituted or substituted as described herein. For example, when the alkyl, cycloalkyl, aryl, and heteroaryl groups of R^2 are substituted, they can be substituted with halo (e.g., Cl, Br, and F), amino, OR^6, wherein R^6 is hydrogen, alkyl, aryl or arylalkyl, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.

[0036] In the compounds of the formulae (I) and (Ia)-(Ii), the alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester groups of R^3 can be unsubstituted or substituted as described herein. For example, when the alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester groups of R^3 are substituted, they can be substituted with halo (e.g., Cl, Br, and F), amino, OR^6, wherein R^6 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.

[0037] In the compounds of the formulae (I) and (Ia)-(Ii), the alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester groups of R^4 can be unsubstituted or substituted as described herein. For example, when the alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester groups of R^4 are substituted, they can be substituted with halo (e.g., Cl, Br, and F), amino, OR^6, wherein R^6 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.

[0038] Examples of compounds of the formulae (I) and (Ia)-(Ii) include, but are not limited to, compounds of the formulae:



,



,



, and

pharmaceutically acceptable salts, polymorphs, prodrugs, solvates or clathrates thereof.

[0039] The disclosure also relates to a compound of the formula (II):



(II)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl (e.g., R^7-C=O or R^8-C=O, wherein R^8 is halo);

X^1 is alkyl (e.g., $-(CH_2)_n-$) or alkenyl;

X^2 is N or CR^5, wherein R^5 is absent (e.g., when X^1 is alkenyl), hydrogen, alkyl or aryl; and

X^3 NR^8 or $C(R^8)_2$, wherein R^8 is H, alkyl (e.g., arylalkyl), acyl (e.g., arylalkyl carbonyl and heterocyclyl carbonyl), aryl, benzyl or heterocyclyl.

[0040] Examples of compounds of the formula (II) include:



, , and



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl (e.g., R^7-C=O or R^8-C=O, wherein R^8 is halo). For example, in each instance, R^6 can independently be F or CF_3.

[0041] The disclosure also relates to a compound of the formula (III):



(III)

wherein:

Y^1 is alkyl (e.g., CH_2), NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

Y^2 is alkyl (e.g., CH_2), NR^8 or O;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl (e.g., heterocyclyl), $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen (e.g., Cl, Br, and F), aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{10} hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl (e.g., heterocyclyl) or $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9, $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen (e.g., Cl, Br, and F), aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl. In compounds of the formula (III), R^9-Y^1 can form the same groups or different groups as R^{10}-Y^2. In compounds of the formula (III), Y^1 can be O or NR^8, wherein R^8 can be alkyl or cycloalkyl.

[0042] Compounds of the formula (III) include compounds of the formulae:


,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl (e.g., CH_2), NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl (e.g., heterocyclyl), $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen (e.g., Cl, Br, and F), aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl (e.g., CF_3), alkoxy (e.g., -OR^{9B}, wherein R^{9B} is alkyl, cycloalkyl or aryl, heteroaryl, acyl, amide or carbamate) or heterocyclyl (e.g., heteroaryl); and

Het^1 and Het^2 are each, independently, a heterocyclyl group, such as furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridinyl, pyrimidinyl, and the like.

[0043] The disclosure also relates to a compound of the formula (IV):



(IV)

wherein:

X^4 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

X^5 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each R^{13} is independently H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl;

R^{14} is hydrogen, amino (e.g., NR^8R^9), alkyl, cycloalkyl, aryl, heteroaryl, acyl (e.g., $C(O)R^9$), thioacyl (e.g., $R^{14}C(S)$), $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen (e.g., Cl, Br, and F), amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{15} is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl (e.g., $C(O)R^9$), thioacyl (e.g., $R^{14}C(S)$), $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen (e.g., Cl, Br, and F), amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or

R^{13} and R^{14}, together with the atoms to which they are each attached, form a heterocyclyl group. In compounds of the formula (IV), R^{14} can form the same groups or different groups as R^{15}.

[0044] In compounds of formula (IV), at least one of R^{14} and R^{15} can be acyl, each of which can be substituted with a group R^9-Y^1-, as the group is defined in compounds of the formula (III). In the compounds of the formula (IV), the compound can be a compound of the formula:


,

,

,

,

, and

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof. In the compounds of the formula (IV), the compound can be a compound of the formula:


,

,

,

, and

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[0045] Compounds of the formula (IV) include compounds of the formulae:


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

, and


or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl (e.g., CH_2), NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl (e.g., heterocyclyl), $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen (e.g., Cl, Br, and F), aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl (e.g., CF_3), alkoxy (e.g., -OR^{9B}, wherein R^{9B} is alkyl, cycloalkyl or aryl, heteroaryl, acyl, amide or carbamate) or heterocyclyl (e.g., heteroaryl); and

Het^1 and Het^2 are each, independently, a heterocyclyl group, such as furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridinyl, pyrimidinyl, and the like. An example of such compounds includes a compound of the formula:



,



, and



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[0046] Compounds of the formula (IV) include compounds of the formulae:



,



,



,



,



,



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

, and


or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl (e.g., CH_2), NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl (e.g., heterocyclyl), $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen (e.g., Cl, Br, and F), aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl (e.g., CF_3), alkoxy (e.g., -OR^{9B}, wherein R^{9B} is alkyl, cycloalkyl or aryl, heteroaryl, acyl, amide or carbamate) or heterocyclyl (e.g., heteroaryl); and

Het^1 and Het^2 are each, independently, a heterocyclyl group, such as furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridinyl, pyrimidinyl, and the like. Examples of such compounds include compounds of the formulae:





,



, and



or

a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[0047] Compounds of the formula (IV) include compounds of the formulae:



,



,



,



,



,



,

 ,

 ,

 ,

 ,

 ,

 ,

 ,

 ,

 ,

 ,





or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl (e.g., CH_2), NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl (e.g., heterocyclyl), $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen (e.g., Cl, Br, and F), aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl (e.g., CF_3), alkoxy (e.g., -OR^{9B},

wherein R^{9B} is alkyl, cycloalkyl or aryl, heteroaryl, acyl, amide or carbamate) or heterocyclyl (e.g., heteroaryl); and

Het^1 and Het^2 are each, independently, a heterocyclyl group, such as furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridinyl, pyrimidinyl, and the like.

[0048] The disclosure also relates to a compound of the formula (V):



(V)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

X^1 is alkyl (e.g., $-(CH_2)_n-$) or alkenyl;

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl;

R^{14} is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen (e.g., Cl, Br, and F), amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

R^{15} is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen (e.g., Cl, Br, and F), amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{16} is H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl; or

R^{14} and R^{15} or R^{15} and R^{16}, together with the atoms to which they are each attached, form a cyclic group (e.g., a cycloalkyl and a heterocyclyl group).

[0049] In compounds of the formula (V), at least one of R^{14} and R^{15} is halogenated aryl (e.g., para-halogenated, as in para-fluoro), such as, e.g., a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[0050] In compounds of the formula (V) R^{16} can be $C(O)R^8$, such that the compound of the formula (V) is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[0051] The disclosure also relates to a compound of the formula (VI):



(VI)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

X^1 is alkyl (e.g., $-(CH_2)_n-$) or alkenyl;

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl;

each R^{13} is H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl;

R^{17} is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and

heteroaryl is optionally substituted with halogen (e.g., Cl, Br, and F), amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

R^{18}-is hydrogen, alkyl, OR^{19} (wherein R^{19} is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl) cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen (e.g., Cl, Br, and F), amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or

R^{17} and R^{18}, together with the atoms to which they are attached, form a cycloalkyl, aryl or heterocyclyl group. In one example, OR^{19} forms a heteroaryl group of the formula:



; or

R^{13} and R^{18}, together with the atoms to which they are each attached, form a heterocyclyl group.

[0052] In compounds of the formula (VI) R^{18} can be $C(O)R^8$, such that the compound of the formula (VI) is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[0053] The disclosure also relates to compounds of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

X^4 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

X^5 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each R^{13} is independently H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl;

R^{14} is hydrogen, amino (e.g., NR^8R^9), alkyl, cycloalkyl, aryl, heteroaryl, acyl (e.g., $C(O)R^9$), thioacyl (e.g., $R^{14}C(S)$), $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen (e.g., Cl, Br, and F), amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{15} and R^{16} are each, independently, hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl (e.g., $C(O)R^9$), thioacyl (e.g., $R^{14}C(S)$), $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen (e.g., Cl, Br, and F), amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or

R^{13} and R^{14}, together with the atoms to which they are each attached, form a heterocyclyl group; or

R^{13} and R^{16}, together with the atoms to which they are each attached, form a cycloalkyl, heterocyclyl or aryl group. An example of such a compound is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[0054] This disclosure also contemplates pharmaceutical compositions comprising one or more compounds and one or more pharmaceutically acceptable excipients. A "pharmaceutical composition" refers to a chemical or biological composition suitable for administration to a subject (e.g., mammal).

Such compositions can be specifically formulated for administration via one or more of a number of routes, including but not limited to buccal, cutaneous, epicutaneous, epidural, infusion, inhalation, intraarterial, intracardial, intracerebroventricular, intradermal, intramuscular, intranasal, intraocular, intraperitoneal, intraspinal, intrathecal, intravenous, oral, parenteral, pulmonary, rectally via an enema or suppository, subcutaneous, subdermal, sublingual, transdermal, and transmucosal. In addition, administration can by means of capsule, drops, foams, gel, gum, injection, liquid, patch, pill, porous pouch, powder, tablet, or other suitable means of administration.

[0055] A "pharmaceutical excipient" or a "pharmaceutically acceptable excipient" is a carrier, sometimes a liquid, in which an active therapeutic agent is formulated. The excipient generally does not provide any pharmacological activity to the formulation, though it can provide chemical and/or biological stability, and release characteristics. Examples of suitable formulations can be found, for example, in Remington, The Science And Practice of Pharmacy, 20th Edition, (Gennaro, A. R., Chief Editor), Philadelphia College of Pharmacy and Science, 2000, which is incorporated by reference in its entirety.

[0056] As used herein "pharmaceutically acceptable carrier" or "excipient" includes, but is not limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Alternatively, the carrier can be suitable for intravenous, intraperitoneal, intramuscular, sublingual, or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0057] Pharmaceutical compositions can be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. The proper fluidity can be

maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.

[0058] In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the compounds described herein can be formulated in a time release formulation, for example in a composition that includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are known to those skilled in the art.

[0059] Oral forms of administration are also contemplated herein. The pharmaceutical compositions of the present invention can be orally administered as a capsule (hard or soft), tablet (film coated, enteric coated or uncoated), powder or granules (coated or uncoated) or liquid (solution or suspension). The formulations can be conveniently prepared by any of the methods well-known in the art. The pharmaceutical compositions of the present invention can include one or more suitable production aids or excipients including fillers, binders, disintegrants, lubricants, diluents, flow agents, buffering agents, moistening agents, preservatives, colorants, sweeteners, flavors, and pharmaceutically compatible carriers.

[0060] For each of the recited embodiments, the compounds can be administered by a variety of dosage forms as known in the art. Any biologically-acceptable dosage form known to persons of ordinary skill in the art, and combinations thereof, are contemplated. Examples of such dosage forms include, without limitation, chewable tablets, quick dissolve tablets, effervescent tablets, reconstitutable powders, elixirs, liquids, solutions, suspensions, emulsions, tablets, multi-layer tablets, bi-layer tablets, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, beads, powders, gum, granules, particles, microparticles, dispersible granules, cachets, douches, suppositories, creams, topicals, inhalants, aerosol inhalants, patches, particle

inhalants, implants, depot implants, ingestibles, injectables (including subcutaneous, intramuscular, intravenous, and intradermal), infusions, and combinations thereof.

[0061] Other compounds which can be included by admixture are, for example, medically inert ingredients (e.g., solid and liquid diluent), such as lactose, dextrosesaccharose, cellulose, starch or calcium phosphate for tablets or capsules, olive oil or ethyl oleate for soft capsules and water or vegetable oil for suspensions or emulsions; lubricating agents such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols; gelling agents such as colloidal clays; thickening agents such as gum tragacanth or sodium alginate, binding agents such as starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinylpyrrolidone; disintegrating agents such as starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuff; sweeteners; wetting agents such as lecithin, polysorbates or laurylsulphates; and other therapeutically acceptable accessory ingredients, such as humectants, preservatives, buffers and antioxidants, which are known additives for such formulations.

[0062] Liquid dispersions for oral administration can be syrups, emulsions, solutions, or suspensions. The syrups can contain as a carrier, for example, saccharose or saccharose with glycerol and/or mannitol and/or sorbitol. The suspensions and the emulsions can contain a carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.

[0063] The amount of active compound in a therapeutic composition according to various embodiments of the present invention can vary according to factors such as the disease state, age, gender, weight, patient history, risk factors, predisposition to disease, administration route, pre-existing treatment regime (e.g., possible interactions with other medications), and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, a single bolus can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the exigencies of therapeutic situation.

[0064] A "dosage unit form," as used herein, refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the

invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in subjects. In therapeutic use for treatment of conditions in mammals (e.g., humans) for which the compounds of the present invention or an appropriate pharmaceutical composition thereof are effective, the compounds of the present invention can be administered in an effective amount. The dosages as suitable for this invention can be a composition, a pharmaceutical composition or any other compositions described herein.

[0065] For each of the recited embodiments, the dosage is typically administered once, twice, or thrice a day, although more frequent dosing intervals are possible. The dosage can be administered every day, every 2 days, every 3 days, every 4 days, every 5 days, every 6 days, and/or every 7 days (once a week). In one embodiment, the dosage can be administered daily for up to and including 30 days, preferably between 7-10 days. In another embodiment, the dosage can be administered twice a day for 10 days. If the patient requires treatment for a chronic disease or condition, the dosage can be administered for as long as signs and/or symptoms persist. The patient can require "maintenance treatment" where the patient is receiving dosages every day for months, years, or the remainder of their lives. In addition, the composition of this invention can be to effect prophylaxis of recurring symptoms. For example, the dosage can be administered once or twice a day to prevent the onset of symptoms in patients at risk, especially for asymptomatic patients.

[0066] The absolute weight of a given compound included in a unit dose for administration to a subject can vary widely. For example, about 0.0001 to about 1 g, or about 0.001 to about 0.5 g, of at least one compound of this disclosure, or a plurality of compounds can be administered. Alternatively, the unit dosage can vary from about 0.001 g to about 2g, from about 0.005 g to about 0.5 g, from about 0.01 g to about 0.25 g, from about 0.02 g to about 0.2 g, from about 0.03 g to about 0.15 g, from about 0.04 g to about 0.12 g, or from about 0.05 g to about 0.1 g.

[0067] Daily doses of the compounds can vary as well. Such daily doses can range, for example, from about 0.01 g/day to about 10 g/day, from about 0.02 g/day to about 5 g/day, from about 0.03 g/day to about 4 g/day, from about 0.04 g/day to about 3 g/day, from about 0.05 g/day to about 2 g/day, and from about 0.05 g/day to about 1 g/day.

[0068] It will be appreciated that the amount of compound(s) for use in treatment will vary not only with the particular carrier selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient. Ultimately the attendant health care provider may determine proper dosage.

[0069] The compositions described herein can be administered in any of the following routes: buccal, epicutaneous, epidural, infusion, inhalation, intraarterial, intracardial, intracerebroventricular, intradermal, intramuscular, intranasal, intraocular, intraperitoneal, intraspinal, intrathecal, intravenous, oral, parenteral, pulmonary, rectally via an enema or suppository, subcutaneous, subdermal, sublingual, transdermal, and transmucosal. The preferred routes of administration are buccal and oral. The administration can be local, where the composition is administered directly, close to, in the locality, near, at, about, or in the vicinity of, the site(s) of disease, e.g., inflammation, or systemic, wherein the composition is given to the patient and passes through the body widely, thereby reaching the site(s) of disease. Local administration can be administration to, for example, tissue, organ, and/or organ system, which encompasses and/or is affected by the disease, and/or where the disease signs and/or symptoms are active or are likely to occur. Administration can be topical with a local effect, composition is applied directly where its action is desired. Administration can be enteral wherein the desired effect is systemic (non-local), composition is given via the digestive tract. Administration can be parenteral, where the desired effect is systemic, composition is given by other routes than the digestive tract.

[0070] The compositions can include the compounds described herein in a "therapeutically effective amount." Such a therapeutically effective amount is an amount sufficient to obtain the desired physiological effect, such as a reduction of at least one symptom of cancer or an inflammatory disease or condition.

[0071] The compositions contemplated herein can contain other ingredients such as chemotherapeutic agents, anti-inflammatory agents, anti-viral agents, antibacterial agents, antimicrobial agents, immunomodulatory drugs, such as lenalidomide, pomalidomide or thalidomide, histone deacetylase inhibitors, such as panobinostat, preservatives or combinations thereof.

[0072] This disclosure also includes methods for treating neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS, comprising administering a therapeutically effective amount of at least one of the compounds described herein (e.g., fluspirilene or compounds of the formulae (I), (Ia)-(Ii), and (II)-(VI)) to a subject in

need thereof. This disclosure also includes methods for reducing, substantially eliminating or eliminating dysregulation of proteostasis comprising administering a therapeutically effective amount of at least one of the compounds described herein (e.g., fluspirilene or compounds of the formulae (I), (Ia)-(Ii), and (II)-(VI)) to a subject in need thereof. This disclosure also includes methods for reducing, substantially eliminating or eliminating the accumulation of intrinsically disordered proteins (e.g., α-syn) comprising administering a therapeutically effective amount of at least one of the compounds described herein (e.g., fluspirilene or compounds of the formulae (I), (Ia)-(Ii), and (II)-(VI)) to a subject in need thereof.

[0073] As used herein, the terms "treat" and "treating" are not limited to the case where the subject (e.g. patient) is cured and the disease is eradicated. Rather, treatment that merely reduces symptoms, and/or delays disease progression is also contemplated.

[0074] The pharmaceutical compositions disclosed herein can have the ability to effectively treat new patient segments where proteasome inhibition and reduced toxicity is desired or warranted.

[0075] The compounds and methods described herein can be used prophylactically or therapeutically. The term "prophylactic" or "therapeutic" treatment refers to administration of a drug to a host before or after onset of a disease or condition. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate or maintain the existing unwanted condition or side effects therefrom). Administering the compounds described herein (including enantiomers and salts thereof) is contemplated in both a prophylactic treatment (e.g. to patients at risk for disease, such as elderly patients who, because of their advancing age, are at risk for arthritis, cancer, and the like) and therapeutic treatment (e.g. to patients with symptoms of disease or to patients diagnosed with disease).

[0076] The term "therapeutically effective amount" as used herein, refers to that amount of one or more compounds of the various examples of the present invention that elicits a biological or medicinal response in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated. In some examples, the therapeutically effective amount is that which can treat or alleviate the disease or symptoms of the disease at a

reasonable benefit/risk ratio applicable to any medical treatment. However, it is to be understood that the total daily usage of the compounds and compositions described herein can be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically-effective dose level for any particular patient will depend upon a variety of factors, including the condition being treated and the severity of the condition; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender and diet of the patient: the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidentally with the specific compound employed; and like factors well known to the researcher, veterinarian, medical doctor or other clinician. It is also appreciated that the therapeutically effective amount can be selected with reference to any toxicity, or other undesirable side effect, that might occur during administration of one or more of the compounds described herein.

[0077] The term "alkyl" as used herein refers to substituted or unsubstituted straight chain, branched and cyclic, saturated mono- or bi-valent groups having from 1 to 20 carbon atoms, 10 to 20 carbon atoms, 12 to 18 carbon atoms, 6 to about 10 carbon atoms, 1 to 10 carbons atoms, 1 to 8 carbon atoms, 2 to 8 carbon atoms, 3 to 8 carbon atoms, 4 to 8 carbon atoms, 5 to 8 carbon atoms, 1 to 6 carbon atoms, 2 to 6 carbon atoms, 3 to 6 carbon atoms, or 1 to 3 carbon atoms. Examples of straight chain mono-valent (C_1-C_{20})-alkyl groups include those with from 1 to 8 carbon atoms such as methyl (i.e., CH_3), ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl groups. Examples of branched mono-valent (C_1-C_{20})-alkyl groups include isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, and isopentyl. Examples of straight chain bi-valent (C_1-C_{20})alkyl groups include those with from 1 to 6 carbon atoms such as -CH_2-, -CH_2CH_2-, -$CH_2CH_2CH_2$-, -$CH_2CH_2CH_2CH_2$-, and -$CH_2CH_2CH_2CH_2CH_2$-. Examples of branched bi-valent alkyl groups include –$CH(CH_3)CH_2$- and –$CH_2CH(CH_3)CH_2$-. Examples of cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopently, cyclohexyl, cyclooctyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, and bicyclo[2.2.1]heptyl. Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like. In some embodiments, alkyl includes a combination of substituted and unsubstituted alkyl. As an example, alkyl, and also (C_1)alkyl, includes methyl and substituted methyl. As a particular example,

(C_1)alkyl includes benzyl. As a further example, alkyl can include methyl and substituted (C_2-C_8)alkyl. Alkyl can also include substituted methyl and unsubstituted (C_2-C_8)alkyl. In some embodiments, alkyl can be methyl and C_2-C_8 linear alkyl. In some embodiments, alkyl can be methyl and C_2-C_8 branched alkyl. The term methyl is understood to be $-CH_3$, which is not substituted. The term methylene is understood to be $-CH_2-$, which is not substituted. For comparison, the term (C_1)alkyl is understood to be a substituted or an unsubstituted $-CH_3$ or a substituted or an unsubstituted $-CH_2-$. Representative substituted alkyl groups can be substituted one or more times with any of the groups listed herein, for example, cycloalkyl, heterocyclyl, aryl, amino, haloalkyl, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups. As further example, representative substituted alkyl groups can be substituted one or more fluoro, chloro, bromo, iodo, amino, amido, alkyl, alkoxy, alkylamido, alkenyl, alkynyl, alkoxycarbonyl, acyl, formyl, arylcarbonyl, aryloxycarbonyl, aryloxy, carboxy, haloalkyl, hydroxy, cyano, nitroso, nitro, azido, trifluoromethyl, trifluoromethoxy, thio, alkylthio, arylthiol, alkylsulfonyl, alkylsulfinyl, dialkylaminosulfonyl, sulfonic acid, carboxylic acid, dialkylamino and dialkylamido. In some embodiments, representative substituted alkyl groups can be substituted from a set of groups including amino, hydroxy, cyano, carboxy, nitro, thio and alkoxy, but not including halogen groups. Thus, in some embodiments alkyl can be substituted with a non-halogen group. For example, representative substituted alkyl groups can be substituted with a fluoro group, substituted with a bromo group, substituted with a halogen other than bromo, or substituted with a halogen other than fluoro. In some embodiments, representative substituted alkyl groups can be substituted with one, two, three or more fluoro groups or they can be substituted with one, two, three or more non-fluoro groups. For example, alkyl can be trifluoromethyl, difluoromethyl, or fluoromethyl, or alkyl can be substituted alkyl other than trifluoromethyl, difluoromethyl or fluoromethyl. Alkyl can be haloalkyl or alkyl can be substituted alkyl other than haloalkyl. The term "alkyl" also generally refers to alkyl groups that can comprise one or more heteroatoms in the carbon chain. Thus, for example, "alkyl" also encompasses groups such as $-[(CH_2)_pO]_qH$ and the like.

[0078] The term "alkenyl" as used herein refers to substituted or unsubstituted straight chain, branched and cyclic, saturated mono- or bi-valent groups having at least one carbon-carbon double bond and from 2 to 20 carbon atoms, 10 to 20 carbon atoms, 12 to 18 carbon atoms, 6 to about 10 carbon atoms, 2 to 10 carbons atoms, 2 to 8 carbon atoms, 3 to 8 carbon atoms, 4 to 8

carbon atoms, 5 to 8 carbon atoms, 2 to 6 carbon atoms, 3 to 6 carbon atoms, 4 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 to 3 carbon atoms. The double bonds can be be trans or cis orientation. The double bonds can be terminal or internal. The alkenyl group can be attached via the portion of the alkenyl group containing the double bond, e.g., vinyl, propen-1-yl and buten-1-yl, or the alkenyl group can be attached via a portion of the alkenyl group that does not contain the double bond, e.g., penten-4-yl. Examples of mono-valent (C_2-C_{20})-alkenyl groups include those with from 1 to 8 carbon atoms such as vinyl, propenyl, propen-1-yl, propen-2-yl, butenyl, buten-1-yl, buten-2-yl, sec-buten-1-yl, sec-buten-3-yl, pentenyl, hexenyl, heptenyl and octenyl groups. Examples of branched mono-valent (C_2-C_{20})-alkenyl groups include isopropenyl, iso-butenyl, sec-butenyl, t-butenyl, neopentenyl, and isopentenyl. Examples of straight chain bi-valent (C_2-C_{20})alkenyl groups include those with from 2 to 6 carbon atoms such as -CHCH-, -$CHCHCH_2$-, -$CHCHCH_2CH_2$-, and -$CHCHCH_2CH_2CH_2$-. Examples of branched bi-valent alkyl groups include --$C(CH_3)CH$- and --$CHC(CH_3)CH_2$-. Examples of cyclic alkenyl groups include cyclopentenyl, cyclohexenyl and cyclooctenyl. It is envisaged that alkenyl can also include masked alkenyl groups, precursors of alkenyl groups or other related groups. As such, where alkenyl groups are described it, compounds are also envisaged where a carbon-carbon double bond of an alkenyl is replaced by an epoxide or aziridine ring. Substituted alkenyl also includes alkenyl groups which are substantially tautomeric with a non-alkenyl group. For example, substituted alkenyl can be 2-aminoalkenyl, 2-alkylaminoalkenyl, 2-hydroxyalkenyl, 2-hydroxyvinyl, 2-hydroxypropenyl, but substituted alkenyl is also understood to include the group of substituted alkenyl groups other than alkenyl which are tautomeric with non-alkenyl containing groups. In some embodiments, alkenyl can be understood to include a combination of substituted and unsubstituted alkenyl. For example, alkenyl can be vinyl and substituted vinyl. For example, alkenyl can be vinyl and substituted (C_3-C_8)alkenyl. Alkenyl can also include substituted vinyl and unsubstituted (C_3-C_8)alkenyl. Representative substituted alkenyl groups can be substituted one or more times with any of the groups listed herein, for example, monoalkylamino, dialkylamino, cyano, acetyl, amido, carboxy, nitro, alkylthio, alkoxy, and halogen groups. As further example, representative substituted alkenyl groups can be substituted one or more fluoro, chloro, bromo, iodo, amino, amido, alkyl, alkoxy, alkylamido, alkenyl, alkynyl, alkoxycarbonyl, acyl, formyl, arylcarbonyl, aryloxycarbonyl, aryloxy, carboxy, haloalkyl, hydroxy, cyano, nitroso, nitro, azido, trifluoromethyl, trifluoromethoxy,

thio, alkylthio, arylthiol, alkylsulfonyl, alkylsulfinyl, dialkylaminosulfonyl, sulfonic acid, carboxylic acid, dialkylamino and dialkylamido. In some embodiments, representative substituted alkenyl groups can be substituted from a set of groups including monoalkylamino, dialkylamino, cyano, acetyl, amido, carboxy, nitro, alkylthio and alkoxy, but not including halogen groups. Thus, in some embodiments alkenyl can be substituted with a non-halogen group. In some embodiments, representative substituted alkenyl groups can be substituted with a fluoro group, substituted with a bromo group, substituted with a halogen other than bromo, or substituted with a halogen other than fluoro. For example, alkenyl can be 1-fluorovinyl, 2-fluorovinyl, 1,2-difluorovinyl, 1,2,2-trifluorovinyl, 2,2-difluorovinyl, trifluoropropen-2-yl, 3,3,3-trifluoropropenyl, 1-fluoropropenyl, 1-chlorovinyl, 2-chlorovinyl, 1,2-dichlorovinyl, 1,2,2-trichlorovinyl or 2,2-dichlorovinyl. In some embodiments, representative substituted alkenyl groups can be substituted with one, two, three or more fluoro groups or they can be substituted with one, two, three or more non-fluoro groups.

[0079] The term "alkynyl" as used herein, refers to substituted or unsubstituted straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms. Thus, alkynyl groups have from 2 to 50 carbon atoms, 2 to 20 carbon atoms, 10 to 20 carbon atoms, 12 to 18 carbon atoms, 6 to about 10 carbon atoms, 2 to 10 carbons atoms, 2 to 8 carbon atoms, 3 to 8 carbon atoms, 4 to 8 carbon atoms, 5 to 8 carbon atoms, 2 to 6 carbon atoms, 3 to 6 carbon atoms, 4 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 to 3 carbon atoms. Examples include, but are not limited to ethynyl, propynyl, propyn-1-yl, propyn-2-yl, butynyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, butyn-4-yl, pentynyl, pentyn-1-yl, hexynyl, Examples include, but are not limited to --C≡CH, -C≡C(CH_3), -C≡C(CH_2CH_3), -CH_2C≡CH, -CH_2C≡C(CH_3), and -CH_2C≡C(CH_2CH_3) among others.

[0080] The term "aryl" as used herein refers to substituted or unsubstituted univalent groups that are derived by removing a hydrogen atom from an arene, which is a cyclic aromatic hydrocarbon, having from 6 to 20 carbon atoms, 10 to 20 carbon atoms, 12 to 20 carbon atoms, 6 to about 10 carbon atoms or 6 to 8 carbon atoms. Examples of (C_6-C_{20})aryl groups include phenyl, napthalenyl, azulenyl, biphenylyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, anthracenyl groups. Examples include substituted phenyl, substituted napthalenyl, substituted azulenyl, substituted biphenylyl, substituted indacenyl, substituted fluorenyl, substituted

phenanthrenyl, substituted triphenylenyl, substituted pyrenyl, substituted naphthacenyl, substituted chrysenyl, and substituted anthracenyl groups. Examples also include unsubstituted phenyl, unsubstituted napthalenyl, unsubstituted azulenyl, unsubstituted biphenylyl, unsubstituted indacenyl, unsubstituted fluorenyl, unsubstituted phenanthrenyl, unsubstituted triphenylenyl, unsubstituted pyrenyl, unsubstituted naphthacenyl, unsubstituted chrysenyl, and unsubstituted anthracenyl groups. Aryl includes phenyl groups and also non-phenyl aryl groups. From these examples, it is clear that the term (C_6-C_{20})aryl encompasses mono- and polycyclic (C_6-C_{20})aryl groups, including fused and non-fused polycyclic (C_6-C_{20})aryl groups.

[0081] The term "heterocyclyl" as used herein refers to substituted aromatic, unsubstituted aromatic, substituted non-aromatic, and unsubstituted non-aromatic rings containing 3 or more atoms in the ring, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. Thus, a heterocyclyl can be a cycloheteroalkyl, or a heteroaryl, or if polycyclic, any combination thereof. In some embodiments, heterocyclyl groups include 3 to about 20 ring members, whereas other such groups have 3 to about 15 ring members. In some embodiments, heterocyclyl groups include heterocyclyl groups that include 3 to 8 carbon atoms (C_3-C_8), 3 to 6 carbon atoms (C_3-C_6) or 6 to 8 carbon atoms (C_6-C_8). A heterocyclyl group designated as a C_2-heterocyclyl can be a 5-membered ring with two carbon atoms and three heteroatoms, a 6-membered ring with two carbon atoms and four heteroatoms and so forth. Likewise a C_4-heterocyclyl can be a 5-membered ring with one heteroatom, a 6-membered ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms equals the total number of ring atoms. A heterocyclyl ring can also include one or more double bonds. A heteroaryl ring is an embodiment of a heterocyclyl group. The phrase "heterocyclyl group" includes fused ring species including those that include fused aromatic and non-aromatic groups. Representative heterocyclyl groups include, but are not limited to piperidynyl, piperazinyl, morpholinyl, furanyl, pyrrolidinyl, pyridinyl, pyrazinyl, pyrimidinyl, triazinyl, thiophenyl, tetrahydrofuranyl, pyrrolyl, oxazolyl, imidazolyl, triazyolyl, tetrazolyl, benzoxazolinyl, and benzimidazolinyl groups. For example, heterocyclyl groups include, without limitation:



, and , wherein X^4 represents H, (C_1-C_{20})alkyl, (C_6-C_{20})aryl or an amine protecting group (e.g., a t-butyloxycarbonyl group) and wherein the heterocyclyl group can be substituted or unsubstituted. A nitrogen-containing heterocyclyl group is a heterocyclyl group containing a nitrogen atom as an atom in the ring. In some embodiments, the heterocyclyl is other than thiophene or substituted thiophene. In some embodiments, the heterocyclyl is other than furan or substituted furan.

[0082] The term "alkoxy" as used herein refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined herein. Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like. Examples of branched alkoxy include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like. Examples of cyclic alkoxy include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. An alkoxy group can include one to about 12-20 or about 12-40 carbon atoms bonded to the oxygen atom, and can further include double or triple bonds, and can also include heteroatoms. Thus, alkyoxy also includes an oxygen atom connected to an alkyenyl group and oxygen atom connected to an alkynyl group. For example, an allyloxy group is an alkoxy group within the meaning herein. A methoxyethoxy group is also an alkoxy group within the meaning herein, as is a methylenedioxy group in a context where two adjacent atoms of a structure are substituted therewith.

[0083] The term "aryloxy" as used herein refers to an oxygen atom connected to an aryl group as are defined herein.

[0084] The term "aralkyl" and "arylalkyl" as used herein refers to alkyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined herein. Representative aralkyl groups include benzyl, biphenylmethyl and phenylethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl. Aralkenyl groups are alkenyl

groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined herein.

[0085] The terms "halo," "halogen," or "halide" group, as used herein, by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.

[0086] The term "amine" and "amino" as used herein refers to a substituent of the form $-NH_2$, $-NHR$, $-NR_2$, $-NR_3^+$, wherein each R is independently selected, and protonated forms of each, except for $-NR_3^+$, which cannot be protonated. Accordingly, any compound substituted with an amino group can be viewed as an amine. An "amino group" within the meaning herein can be a primary, secondary, tertiary, or quaternary amino group. An "alkylamino" group includes a monoalkylamino, dialkylamino, and trialkylamino group.

[0087] The term "acyl" as used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom is also bonded to another carbon atom, which can be part of a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, group or the like.

[0088] The term "formyl" as used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom is also bonded to a hydrogen atom.

[0089] The term "alkoxycarbonyl" as used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom is also bonded to an oxygen atom which is further bonded to an alkyl group. Alkoxycarbonyl also includes the group where a carbonyl carbon atom is also bonded to an oxygen atom which is further bonded to an alkyenyl group. Alkoxycarbonyl also includes the group where a carbonyl carbon atom is also bonded to an oxygen atom which is further bonded to an alkynyl group. In a further case, which is included in the definition of alkoxycarbonyl as the term is defined herein, and is also included in the term "aryloxycarbonyl," the carbonyl carbon atom is bonded to an oxygen atom which is bonded to an aryl group instead of an alkyl group.

[0090] The term "arylcarbonyl" as used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom is also bonded to an aryl group.

[0091] The term "alkylamido" as used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom is also bonded to a nitrogen group which is bonded to one

or more alkyl groups. In a further case, which is also an alkylamido as the term is defined herein, the carbonyl carbon atom is bonded to a nitrogen atom which is bonded to one or more aryl group instead of, or in addition to, the one or more alkyl group. In a further case, which is also an alkylamido as the term is defined herein, the carbonyl carbon atom is bonded to an nitrogen atom which is bonded to one or more alkenyl group instead of, or in addition to, the one or more alkyl and or/aryl group. In a further case, which is also an alkylamido as the term is defined herein, the carbonyl carbon atom is bonded to a nitrogen atom which is bonded to one or more alkynyl group instead of, or in addition to, the one or more alkyl, alkenyl and/or aryl group.

[0092] The term "carboxy" as used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom is also bonded to a hydroxy group or oxygen anion so as to result in a carboxylic acid or carboxylate. Carboxy also includes both the protonated form of the carboxylic acid and the salt form. For example, carboxy can be understood as COOH or CO_2H.

[0093] The term "amido" or "amide" as used herein refers to a group having the formula C(O)NRR, wherein R is defined herein and can each independently be, e.g., hydrogen, alkyl, aryl or each R, together with the nitrogen atom to which they are attached, form a heterocyclyl group.

[0094] The term "alkylthio" as used herein refers to a sulfur atom connected to an alkyl, alkenyl,or alkynyl group as defined herein.

[0095] The term "arylthio" as used herein refers to a sulfur atom connected to an aryl group as defined herein.

[0096] The term "alkylsulfonyl" as used herein refers to a sulfonyl group connected to an alkyl, alkenyl,or alkynyl group as defined herein.

[0097] The term "alkylsulfinyl" as used herein refers to a sulfinyl group connected to an alkyl, alkenyl, or alkynyl group as defined herein.

[0098] The term "dialkylaminosulfonyl" as used herein refers to a sulfonyl group connected to a nitrogen further connected to two alkyl groups, as defined herein, and which can optionally be linked together to form a ring with the nitrogen. This term also includes the group where the nitrogen is further connected to one or two alkenyl groups in place of the alkyl groups.

[0099] The term "dialkylamino" as used herein refers to an amino group connected to two alkyl groups, as defined herein, and which can optionally be linked together to form a ring with the nitrogen. This term also includes the group

where the nitrogen is further connected to one or two alkenyl groups in place of the alkyl groups.

[00100] The term "dialkylamido" as used herein refers to an amido group connected to two alkyl groups, as defined herein, and which can optionally be linked together to form a ring with the nitrogen. This term also includes the group where the nitrogen is further connected to one or two alkenyl groups in place of the alkyl groups.

[00101] The term "substituted" as used herein refers to a group that is substituted with one or more groups including, but not limited to, the following groups: halogen (e.g., F, Cl, Br, and I), R, OR, ROH (e.g., CH_2OH), $OC(O)N(R)_2$ (also known as carbamate), CN, NO, NO_2, ONO_2, azido, CF_3, OCF_3, methylenedioxy, ethylenedioxy, $(C_3\text{-}C_{20})$heteroaryl, $N(R)_2$, $Si(R)_3$, SR, SOR, SO_2R, $SO_2N(R)_2$, SO_3R, $P(O)(OR)_2$, $OP(O)(OR)_2$, C(O)R, C(O)C(O)R, $C(O)CH_2C(O)R$, C(S)R, C(O)OR, OC(O)R, $C(O)N(R)_2$, C(O)N(R)OH, $OC(O)N(R)_2$, $C(S)N(R)_2$, $(CH_2)_{0\text{-}2}N(R)C(O)R$, $(CH_2)_{0\text{-}2}N(R)N(R)_2$, N(R)N(R)C(O)R, N(R)N(R)C(O)OR, $N(R)N(R)CON(R)_2$, $N(R)SO_2R$, $N(R)SO_2N(R)_2$, N(R)C(O)OR, N(R)C(O)R, N(R)C(S)R, $N(R)C(O)N(R)_2$, $N(R)C(S)N(R)_2$, N(COR)COR, N(OR)R, $C(=NH)N(R)_2$, C(O)N(OR)R, or C(=NOR)R wherein R can be hydrogen, $(C_1\text{-}C_{20})$alkyl, $(C_6\text{-}C_{20})$aryl, heterocyclyl or polyalkylene oxide groups, such as polyalkylene oxide groups of the formula $-(CH_2CH_2O)_f\text{-R-OR}$, $-(CH_2CH_2CH_2O)_g\text{-R-OR}$, $-(CH_2CH_2O)_f(CH_2CH_2CH_2O)_g\text{-R-OR}$ each of which can, in turn, be substituted or unsubstituted and wherein f and g are each independently an integer from 1 to 50 (e.g., 1 to 10, 1 to 5, 1 to 3 or 2 to 5). Substituted also includes a group that is substituted with one or more groups including, but not limited to, the following groups: fluoro, chloro, bromo, iodo, amino, amido, alkyl, hydroxy, alkoxy, alkylamido, alkenyl, alkynyl, alkoxycarbonyl, acyl, formyl, arylcarbonyl, aryloxycarbonyl, aryloxy, carboxy, haloalkyl, hydroxy, cyano, nitroso, nitro, azido, trifluoromethyl, trifluoromethoxy, thio, alkylthio, arylthiol, alkylsulfonyl, alkylsulfinyl, dialkylaminosulfonyl, sulfonic acid, carboxylic acid, dialkylamino and dialkylamido. Where there are two or more adjacent substituents, the substituents can be linked to form a carbocyclic or heterocyclic ring. Such adjacent groups can have a vicinal or germinal relationship, or they can be adjacent on a ring in, e.g., an ortho-arrangement. Each instance of substituted is understood to be independent. For example, a substituted aryl can be substituted with bromo and a substituted heterocycle on the same compound can be substituted with alkyl. It is envisaged that a substituted group can be substituted with one or more non-fluoro groups. As another example, a

substituted group can be substituted with one or more non-cyano groups. As another example, a substituted group can be substituted with one or more groups other than haloalkyl. As yet another example, a substituted group can be substituted with one or more groups other than tert-butyl. As yet a further example, a substituted group can be substituted with one or more groups other than trifluoromethyl. As yet even further examples, a substituted group can be substituted with one or more groups other than nitro, other than methyl, other than methoxymethyl, other than dialkylaminosulfonyl, other than bromo, other than chloro, other than amido, other than halo, other than benzodioxepinyl, other than polycyclic heterocyclyl, other than polycyclic substituted aryl, other than methoxycarbonyl, other than alkoxycarbonyl, other than thiophenyl, or other than nitrophenyl, or groups meeting a combination of such descriptions. Further, substituted is also understood to include fluoro, cyano, haloalkyl, tert-butyl, trifluoromethyl, nitro, methyl, methoxymethyl, dialkylaminosulfonyl, bromo, chloro, amido, halo, benzodioxepinyl, polycyclic heterocyclyl, polycyclic substituted aryl, methoxycarbonyl, alkoxycarbonyl, thiophenyl, and nitrophenyl groups.

[00102] In some instances, the compounds described herein (e.g., compounds of the formulae (I), (Ia)-(Ii), (II)-(VI)) can contain chiral centers. All diastereomers of the compounds described herein are contemplated herein, as well as racemates.

[00103] As used herein, the term "salts" and "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids. Pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic, and the like.

[00104] Pharmaceutically acceptable salts can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. In some instances, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric (or larger) amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, the disclosure of which is hereby incorporated by reference.

[00105] The term "solvate" means a compound, or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.

[00106] The term "prodrug" means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide an active compound, particularly a compound of the invention. Examples of prodrugs include, but are not limited to, derivatives and metabolites of a compound of the invention that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Specific prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid. The carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described by Burger's Medicinal Chemistry and Drug Discovery 6th ed. (Donald J. Abraham ed., 2001, Wiley) and Design and Application of Prodrugs (H. Bundgaard ed., 1985, Harwood Academic Publishers GmbH).

[00107] As used herein, the term "subject" or "patient" refers to any organism to which a composition described herein can be administered, e.g., for experimental, diagnostic, prophylactic and/or therapeutic purposes. Subject refers to a mammal receiving the compositions disclosed herein or subject to disclosed methods. It is understood and herein contemplated that "mammal" includes but is not limited to humans, non-human primates, cows, horses, dogs, cats, mice, rats, rabbits, and guinea pigs.

[00108] Each embodiment described above is envisaged to be applicable in each combination with other embodiments described herein. For example, embodiments corresponding to formula (I) are equally envisaged as being

applicable to formulae (Ia)-(Ii), and (II)-(VI)). Likewise, embodiments corresponding to formula (II) are equally envisaged as being applicable to formulae (I), (Ia)-(Ii), and (III)-(VI) and so forth.

[00109] Values expressed in a range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range were explicitly recited. For example, a range of "about 0.1% to about 5%" or "about 0.1% to 5%" should be interpreted to include not just about 0.1% to about 5%, but also the individual values (*e.g.*, 1%, 2%, 3%, and 4%) and the sub-ranges (*e.g.*, 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the indicated range. The statement "about X to Y" has the same meaning as "about X to about Y," unless indicated otherwise. Likewise, the statement "about X, Y, or about Z" has the same meaning as "about X, about Y, or about Z," unless indicated otherwise.

[00110] In this document, the terms "a," "an," or "the" are used to include one or more than one unless the context clearly dictates otherwise. The term "or" is used to refer to a nonexclusive "or" unless otherwise indicated. In addition, it is to be understood that the phraseology or terminology employed herein, and not otherwise defined, is for the purpose of description only and not of limitation. Any use of section headings is intended to aid reading of the document and is not to be interpreted as limiting; information that is relevant to a section heading may occur within or outside of that particular section. Furthermore, all publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.

[00111] The term "about" as used herein can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range.

[00112] The term "substantially" as used herein refers to a majority of, or mostly, as in at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more.

[00113] The terms and expressions that have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown

and described or portions thereof, but it is recognized that various modifications are possible within the scope of the embodiments of the present disclosure. Thus, it should be understood that although the present disclosure has been specifically disclosed by specific embodiments and optional features, modification and variation of the concepts herein disclosed can be resorted to by those of ordinary skill in the art, and that such modifications and variations are considered to be within the scope of embodiments of the present disclosure

[00114] The invention is now described with reference to the following Examples. The following working examples therefore, are provided for the purpose of illustration only and specifically point out certain embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure. Therefore, the examples should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

EXAMPLES

[00115] The present disclosure can be better understood by reference to the following examples which are offered by way of illustration. The disclosure is not limited to the examples given herein.

Introduction

[00116] The human proteasome is part of the cellular machinery that regulates protein degradation. Most proteins are degraded by the 26S proteasome via a ubiquitin-dependent mechanism, however intrinsically disordered proteins (unstructured) proteins can also be degraded the 20S isoform of the proteasome via a ubiquitin-independent mechanism. Intrinsically disordered proteins (IDPs) are named for their lack of tertiary structure allowing them to adopt numerous conformations and interact with multiple binding partners. When the synthesis of IDPs outpaces their rate of degradation, they accumulate and induce toxic signaling events that drive many human diseases.

[00117] Arguably the most infamous IDP associated with cancer initiation, progression and relapse is the pro-oncogenic transcription factor, c-MYC. Over-expression of c-MYC is the driving force in an astonishing 60-70% of all human cancers including multiple myeloma, histiocytic sarcoma, myeloid leukemia, glioblastoma, melanoma, breast cancer, colon cancer, cervical cancer, small-cell lung carcinoma, and osteosarcoma. Small molecule 20S proteasome activators can reduce c-MYC protein levels and therefore prevent the initiation progression and relapse in c-MYC driven cancers.

[00118] The disclosure relates to small molecule 20S proteasome

activators of the formulae (I), (Ia)-(Ii), and (II)-(VI) as therapeutic agents to treat amyloidogenic diseases including neurodegenerative diseases and type II diabetes. Neurodegenerative diseases include: Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD-related disorders, Prion disease, Motor neuron diseases (MND), Huntington's disease (HD), Spinocerebellar ataxia (SCA) and Spinal muscular atrophy (SMA). Overwhelming evidence points towards the accumulation and subsequent oligomerization of intrinsically disordered proteins (IDPs) such as amyloid-b, a-synuclein, polyQ, and dipeptide repeat (DPR) units as the driving causes of these diseases. These soluble oligomeric forms are also responsible for impairing proteasome function, which further drives disease progression. Robust data demonstrates that enhancing proteasome activity prevents the accumulation of IDPs, reduces brain damage, prevents dementia and may be a new therapeutic strategy to treat neurodegenerative diseases.

Methods

[00119] Materials and Reagents. Human 20S proteasome and fluorogenic substrates N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (Suc-LLVY-AMC), carboxyl benzyl-Leu-Leu-Glu-7-amido-4-methylcoumarin (Z-LLE-AMC), tert-butyloxycarbonyl-Leu-Arg-Arg-7-amido-4-methylcoumarin (Boc-LRR-AMC), and bortezomib were obtained from Boston Biochem, Inc. (Cambridge, MA). The PVDF membrane, Clarity western ECL reagent, blocking grade milk, and precast sodium dodecyl sulfate gels were from Bio-Rad (Hercules, CA). The recombinant wild type α-synuclein was obtained from Abcam (Cambridge, MA). Rabbit polyclonal anti-α-synuclein, mouse monoclonal anti-α-synuclein and goat anti-rabbit HRP-linked antibody were purchased from Santa Cruz Biotechnologies (Dallas, TX). The anti-mouse HRP-linked antibody was purchased from Cell Signaling Technology (Danvers, MA). The α-synuclein aggregates were obtained from Novus Biologicals (Littleton, CO). Unless otherwise noted, chemicals were purchased from commercial suppliers and used without further purification.

[00120] Molecular docking studies. Docking was performed using AutoDock vina, supported through computational resources and services provided by the Institute for Cyber-Enabled Research at Michigan State University. The crystal structure of the closed gate human proteasome (h20S) was obtained from the PDB database (PDB ID: 4R3O). Molecules were generated in Perkin Elmer's Chem3D, minimized using the MM2 force field, and converted to PDB. These molecules were uploaded to PyRx and converted to

ligand pdbqt files. Small molecule ligands were then docked against the entirety of the h20S proteasome (grid box 153.2 × 138.0 × 189.4 Å) three times with exhaustiveness set to 1000. Individual poses were manually inspected using Pymol and BIOVIA Discovery Studio 2020.

[00121] Fluorogenic peptide degradation 20S proteasome activity assay. Activity assays were carried out in a 100 µL reaction volume. Different concentrations (1–80 µM) of test compounds were added to a black flat/clear bottom 96-well plate containing 1 nM of human constitutive 20S proteasome, in 50 mM Tris-HCl at pH 7.8, 100 mM NaCl and allowed to incubate for 15 min at 37°C. Fluorogenic substrates were then added and the enzymatic activity measured at 37°C on a SpectraMax M5e spectrometer by measuring the change in fluorescence unit per minute for 1 hour at 380–460 nm. The fluorescence units for the vehicle control were set at a 100%, and the ratio of drug-treated sample set to that of vehicle control was used to calculate the fold change in enzymatic activity. The fluorogenic substrates used were one of the following: Suc-LLVY-AMC (CT-L activity, 20 µM), Z-LLE-AMC (Casp-L activity, 20 µM), Boc-LRR-AMC (T-L activity, 40 µM) or a combination of the three substrates each at 6.67 µM.

[00122] General Experimental Information. Reactions were carried out under a nitrogen atmosphere in flame-dried glassware. Solvents and reagents were purchased from commercial suppliers and used without further purification. Anhydrous THF was distilled over sodium and benzophenone directly before use. Magnetic stirring was used for all reactions. Yields refer to chromatographically and spectroscopically pure compounds unless otherwise noted. Infrared spectra were recorded on a Jasco Series 6600 FTIR spectrometer. ^{1}H and ^{13}C NMR spectra were recorded on a Varian Unity Plus-500 or 600 spectrometers. Chemical shifts are reported relative to the residue peaks of the solvent (CDCl3: 7.26 ppm for 1H and 77.0 ppm for 13C) (DMSO-d6: 2.50 ppm for 1H and 39.5 ppm for 13C). The following abbreviations are used to denote the multiplicities: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, and m = multiplet. HRMS were obtained at the Mass Spectrometry Facility of Michigan State University with a Micromass Q-ToF Ultima API LC-MS/MS mass spectrometer.

[00123] In vitro purified α-synuclein degradation assay (silver stain). Digestion of α-synuclein was carried out in a 50 µL reaction volume made of 50 mM Tris at pH 7.8; 0.33 µM purified α-synuclein and 6.7 nM purified human 20S proteasome. Briefly, 20S proteasome was diluted to 7.58 nM in the reaction buffer. Test compounds or vehicle (1 µL of 50× stock or DMSO) were added to 44 µL of 7.58 nM 20S and incubated at 37°C for 20 min. 5 µL of 3.3 µM α-

synuclein substrate was then added to the reaction mixture and incubated at 37°C for 4 hours. The reactions were quenched with concentrated sodium dodecyl sulfate (SDS) loading buffer. After boiling for 10 min, samples were resolved on a 4–20% Tris-glycine SDS-PAGE gel. The gels were then stained using a Pierce Silver Stain Kit (Thermo Scientific, Rockford IL) and the provided procedure.

[00124] Amyloid beta aggregate preparation. Synthetic amyloid beta was purchased from Eurogentec. To remove preexisting aggregates, synthetic amyloid beta peptide was dissolved in 100% hexafluoroisopropanol (HFIP) and incubated at 37 °C for 2 h. The HFIP was removed and the remaining peptide films were stored at −80 °C until use. Aggregates were prepared by resuspending amyloid beta films with DMSO (50 µL per 1 mg of peptide), followed by addition of ultrapure H_2O (800 µL) and rapid addition of 2 M Tris-base (10 µL) at pH 7.6. The solution was then vortexed for 5 seconds and allowed to incubate at room temperature for 5 minutes. The Amyloid beta mixture was then diluted to the desired concentration and used immediately.

[00125] IDP oligomer inhibition in fluorogenic peptide degradation assay. Assays were carried out in a 100 µL reaction volume. Different concentrations (1–10 µM) of test compounds were added to a black flat/clear bottom 96-well plate containing 1 nM of human constitutive 20S proteasome, in 50 mM Tris-HCl at pH 7.8 and allowed to incubate for 15 min at 37°C. Then, 1 µL of α-synuclein or amyloid beta oligomer mixture of was added to each sample to a final concentration of 500 nM for α-synuclein and 2.5 µM for amyloid beta. This mixture was then allowed to incubate again for 15 min at 37°C. Next, 10 µL of CT-L fluorogenic substrate was added to a final concentration of 20 µM. The enzymatic activity was measured at 37°C on a SpectraMax M5e spectrometer by measuring the change in fluorescence unit per minute for 1 hour at 380–460 nm. The fluorescence units for the vehicle control were set at a 100%, and the ratio of drug-treated or just oligomer-treated samples to the vehicle control was used to calculate the relative enzymatic activity.

[00126] *In vitro* purified α-synuclein oligomer degradation assay (western blot). Digestion of α-synuclein oligomer mixture was carried out in a 50 µL reaction volume made of 50 mM Tris at pH 7.8; 0.33 µM α-synuclein oligomer mixture and 6.7 nM purified human 20S proteasome. Briefly, 20S proteasome was diluted to 7.58 nM in the reaction buffer. Fluspirilene or vehicle (1 µL of 50× stock or DMSO) were added to 44 µL of 7.58 nM 20S and incubated at 37°C for 20 min. The substrate (5 µL of 3.3 µM synuclein oligomer mixture) was then added to the reaction mixture and incubated at 37°C for 24 hours. The reactions

were then quenched with concentrated SDS loading buffer. Samples were resolved on a 4–20% Tris-glycine SDS-PAGE and immunoblotted with mouse monoclonal anti α-synuclein IgG (1:2000) and anti-mouse HRP-linked IgG (1:2000). Blots were developed with ECL western reagent and imaged with an Azure Biosystems 300Q imager.

[00127] **Cell culture.** Human embryonic kidney cells (HEK293T) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 100 units/mL penicillin/streptomycin, at 37 °C with 5% CO_2.

[00128] **Transient transfection of A53T α-synuclein plasmid into HEK-293T cells.** Cells were grown according using the methods stated above to ~50-70% confluency. At this point plasmid prepared with Xfect transfection agent (prepared following manufacturers protocol) was added to the HEK-293 cells and incubated for 4 hours. The media was then replaced with fresh culture media and the cells were returned to the incubator for 24 hours prior to treatment.

[00129] **A53T α-synuclein digestion in HEK-293T cells.** HEK-293T cells were transfected as described above and incubated for 24 hours. The cells were then treated with 100µg/mL of cycloheximide, in combination with either vehicle (DMSO), fluspirilene (10 or 30 µM), N-acylated fluspirilene (10 or 30 µM), bortezomib (100 nM), or a combination thereof for 8 hours. The cells were then lysed using RIPA buffer and the manufacturers protocol. A BCA assay was performed to quantify protein levels and the lysates were normalized to desired concentrations prior to electrophoresis and western blot analysis, performed as described previously.

Example 1: Compound Identification

[00130] The small molecule antipsychotic drug fluspirilene was identified as a promising new scaffold for the development of 20S activators due to its strong enhancement of 20S proteolysis. To assess fluspirilene's 20S proteasome activity, a series of assays were performed using each of three fluorogenic peptide substrates. These substrates were a chymotryptic-like (CT-L), a trypsin-like (T-L) and a caspase-like (Casp-L) substrate, one for each of the catalytic sites of the proteasome. It has been shown that the proteasome's active sites allosterically regulate each other in the presence of their individual substrates. Therefore, a combination of the three probes to represent the overall activity of a 20S activator more accurately in a system in which all catalytic sites are interacting. Fluspirilene activates all three catalytic sites of the 20S proteasome (FIG. 1) and achieved a doubling of activity (hereafter referred to as AC_{200}) using

the combination of probes at 2.2 μM (i.e. AC_{200} 2.2 μM), with a maximum fold enhancement of nearly 10-fold (i.e. 1000%). Moreover, fluspirilene did not enhance the proteolytic activity of the 26S proteasome (FIG. 1A).

Example 2: Design of analogues:

[00131] Fluspirilene is a potent dopamine D2 receptor antagonist that has been used for the treatment of schizophrenia. As such, it has good drug-like properties and penetrates the blood brain barrier (BBB) effectively, which makes it a promising scaffold for the development of novel 20S activators. On the other hand, due to its potent D2 receptor activity it cannot be repurposed therapeutically without modification. Therefore, structural modifications known to reduce the dopamine D2 receptor activity were prepared. *N*-acylated fluspirilene (**16**), was designed to eliminate fluspirilene's D2 receptor activity. In this scaffold, the basicity of the piperidine's amine has been reduced through its conversion to an amide. Molecular docking studies were performed using AutoDock Vina. Fluspirilene and acyl-fluspirilene were found to preferentially bind to the α2-3 intersubunit pocket (FIG. 2A and FIG. 2B). This mode of binding is different from our previously reported 20S proteasome activators which, when docked, preferentially bind to the α1-2 intersubunit pocket of the 20S proteasome. To test the importance of the α2-3 intersubunit pocket, two other analogues of fluspirilene were devised as negative controls.

Example 3: Synthesis

[00132] Fluspirilene was synthesized according to literature, and several derivatives were prepared. As shown in Scheme 1, the diphenyl tails were produced using a Grignard reaction between dihydrofuran-2(3H)-one and two equivalents of aryl magnesium bromide. Subsequent dehydration of the tertiary alcohol was performed via reflux in ethanol with addition of hydrochloric acid. The formed alkenes (compounds **6** and **7**) were reduced using hydrogen gas with palladium on carbon in ethanol overnight to afford compounds **12** and **13**. Bromination via the Appel reaction produced compounds **8**, **9**, **17**, and **18**. Lastly, nucleophilic substitution of the diphenylbutyl halides with 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (**10**) produced fluspirilene derivatives **11**, and **19**, as well as fluspirilene **20**. To produce the acylated scaffold **16**, compound **13** was oxidized to a carboxylic acid using Jones reagent, which was then coupled to **10** using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). Each of the synthesized fluspirilene analogs (compounds **11**, **16** and **19**), compound **10**, and the intermediates (compounds **6**, **7**, **12**–**15**) used in their synthesis were tested for 20S proteasome activity (FIG. 3). To do this, our standard fluorogenic peptide

assay was employed to assess their activity using a combination of the three catalytic site substrates. The results obtained from this screening showed that none of the intermediates were active, but the fluspirilene analogs themselves all showed some degree of activity (FIG. 3). The *N*-acylated analog of fluspirilene (compound **16**) had comparable potency (AC_{200} 1.9 μM, FIG. 3B) to that of fluspirilene (FIG. 3), but a superior maximum fold enhancement (>2000%).



Scheme 1

Reagents and conditions in Scheme 1: (a) dry tetrahydrofuran, reflux, 5 h (b) conc. HCl, ethanol, reflux, 20 h (c) CBr_4, PPh_3, CH_2Cl_2, 0 °C-RT, 5 h (d) **10**, Na_2CO_3, KI, CH_3CN, reflux, 5 h, then RT for 16 h (e) H_2, Pd/C, ethanol, RT,

20 h (f) CrO_3, H_2SO_4, acetone, 0 °C-RT, 16 h (g) 10, EDC, tBuOH, Hunig's base, CH_2Cl_2, RT, 16 h.

Example 4: Docking studies:

[00133] To further analyze why fluspirilene and compound **16** show such promising 20S proteasomal activity while compounds **11** and **19** display lessened activity, BIOVA Discovery Studio 2020 was used to observe the binding pocket interactions of our analogues within the α2-3 intersubunit pocket (FIG. 4). In multiple binding modes, strong hydrogen bond interactions are observed between fluspirilene and compound **16**'s amide N-H and a variety of amino acid residues such as LYS77, ILE65, ASN84, TYR75, and GLN111 (FIG. 4A and FIG. 4B). Comparatively, while compounds **11** and **19** show hydrogen bonding with the amide's carbonyl, they display no interactions between the amide's N-H and any of the above-mentioned amino acid residues (FIG. 4C and 4D). Furthermore, compounds **11** and **19** display less preference for the α2-3 intersubunit pocket, suggesting a strong N-H hydrogen bond interaction is necessary to support preferential binding. Fluspirilene, compound **16**, and compound **19** also display pi-pi interactions with the diphenyl tail, specifically interacting with PHE 60, PHE 61, and TYR154, while compound **11** shows no pi-pi interactions between the amino acid residues and diphenyl tail. This supports our theory that locking the conformation of the diphenyl tail with a double bond prevents binding by limiting the scaffold's conformational flexibility.

Example 5: In vitro testing, 20S activation

[00134] The 20S activity of *N*-acylated fluspirilene (compound **16**) was further assessed in the fluorogenic peptide assay, using each of the individual substrates as well as the combination of the three (FIG. 5). When compared to fluspirilene, the *N*-acylated analog performs similarly using the combination of the three peptide substrate probes, with an AC_{200} of 1.9 μM. Additionally, the *N*-acylated analog achieved better activation of the T-L site, but reduced activation of the CT-L site relative to fluspirilene itself, when tested on the individual fluorescent peptide probes. The *N*-acylated analog achieved higher max fold increases for each substrate/combination (>1500% increase over vehicle) but required slightly higher concentrations to reach doubling of activity at the CT-L (AC_{200} 4.7 μM) and Casp-L (AC_{200} 4.1 μM) sites (FIG. 5).

Example 6: In vitro testing, IDP degradation

[00135] Purified human 20S proteasome was incubated with the compounds, fluspirilene and *N*-acylated fluspirilene (**16**), at various

concentrations, and human α-syn substrate was subsequently added to the mixtures. The resulting digestions were visualized using silver stains. Enhanced 20S activity is measured as a reduction of remaining α-syn when compared to the vehicle control. As shown in FIG. 6, both fluspirilene and *N*-acylated fluspirilene were able to effectively enhance the degradation of α-syn by the 20S proteasome *in vitro*. Both compounds displayed a significant (FIGS. 6B-6C, >50%, $p<0.001$) concentration-depended decrease in a-syn at values near their AC_{200}. These results grant confidence in this novel 20S activator scaffold to induce the degradation of IDPs and prevent their accumulation.

Example 7: Restoring impaired proteasome activity, in vitro

[00136] Proteasome impairment is a major contributor to the accumulation of neurotoxic IDP oligomers. In fact, it was recently shown that IDP oligomers associated with neurodegenerative diseases, such as α-syn, amyloid beta and Huntingtin protein, can directly inhibit the 20S proteasome. This IDP oligomer-induced 20S proteasome impairment has the potential to contribute to further accumulation of the IDPs and thus disease progression. We hypothesized that if 20S proteasome enhancers can protect against IDP-mediated impairment of the 20S proteasome, 20S enhancers may reestablish the clearing of IDPs. To monitor the effects fluspirilene and *N*-acylated fluspirilene on an IDP-oligomer impaired 20S proteasome, purified 20S proteasome was incubated with the compounds and aggregates of α-syn or amyloid beta were introduced following the procedure reported by Smith and co-workers. Consistent with their findings, we found that both α-syn and amyloid beta aggregate mixtures significantly reduced 20S-mediated proteolysis (FIGS. 7A-7D). Importantly, we also found that both fluspirilene and *N*-acylated fluspirilene (**16**) prevented 20S impairment by a-syn oligomers (FIGS. 7A and 7B) as well as amyloid beta oligomers (FIGS. 7C and 7D) in a concentration dependent manner. These studies indicate that the 20S proteasome activators, fluspirilene and *N*-acylated fluspirilene can overcome proteasome impairment by IDP oligomers. α-Syn oligomers, like those that inhibit the 20S proteasome, are thought to exist in a dynamic equilibrium with the monomeric form. According to the studies by Smith and co-workers, the medium size oligomers were associated with 20S inhibition (identified in FIGS. 7E and 7G).

[00137] While not wishing to be bound by any specific theory, it was hypothesized that 20S activators induce degradation of monomeric α-syn and subsequently shift the equilibrium and reduce the toxic inhibitory medium sized oligomers. This was explored by examining α-syn oligomer levels after an

incubation of 24 hours with 20S proteasome, pretreated with one of the activators or vehicle control (DMSO). The remaining α-syn oligomers were visualized using Western blot and the medium sized oligomers (as indicated within the blue block in FIGS. 7E and 7G) were quantified (FIGS. 7E-7H). FIGS. 7E-7H indicates that the addition of either 20S activator, fluspirilene and the new analogue *N*-acylated fluspirilene (**16**), lead to a reduction in overall α-syn oligomers, relative to the vehicle control. This reduction in oligomeric a-syn may account for the restoration of impaired proteasome activity in the presence of these inhibitory oligomers and demonstrate the potential of 20S activators to re-establishing proteostasis in systems where IDP oligomers induce proteasome impairment, as seen in many neurodegenerative diseases.

Example 8: Cellular efficacy:

[00138] The A53T mutation of α-synuclein has been linked to early on-set familial Parkinson's disease and appears to oligomerize faster than the wild-type protein. To examine the effect of fluspirilene and *N*-acylated fluspirilene (**16**) on the degradation of the pathogenic A53T a-synuclein mutant in cells, we transiently transfected the A53T α-synuclein plasmid into HEK-293T cells and probed for A53T a-synuclein protein in the absence and presence of compound. To ensure that the observed effect was due to changes at the protein level, cycloheximide was added to block protein synthesis. As shown in FIG. 8 both fluspirilene and *N*-acylated fluspirilene effectively reduced the accumulation of A53T a-synuclein protein within 8 hours of treatment in a concentration dependent manner. Importantly, the effects of the 20S proteasome enhancer *N*-acylated fluspirilene (**16**) was abrogated by blocking proteasome activity, using the proteasome inhibitor, bortezomib (BTZ), thereby implicating the proteasome as the protease responsible for this degradation.

Example 9: Fluspirilene derivatives enhance proteasome activity

[00139] Each of the synthesized fluspirilene analogs (compounds **11**, **16** and **19**) and the intermediates (compounds **6**, **7**, **12–15**) used in their synthesis were tested for 20S proteasome activity. FIG. 5 shows the results of extended fluorogenic peptide analysis of *N*-acylated fluspirilene. FIG. 3 shows the results of extended fluorogenic peptide analysis of *N*-acylated of compounds **16**, **19**, **11**. These data were collected in triplicate (n=3). Error bars denote standard deviation. Whereas all of the intermediates (**6**, **7**, and **12-15**) were inactive, compound **11** and **19** displayed moderate activity. Compound **16**, acyl fluspirilene displayed excellent activity.

[00140] The disclosure provides for the following example embodiments, the numbering of which is not to be construed as designating levels of importance:

[00141] Embodiment 1 relates to a compound of the formula (I):



(I)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:

R^1 is alkyl, alkenyl, cycloalkyl, aryl or heteroaryl; and

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl.

[00142] Embodiment 2 relates to the compound of Embodiment 1, wherein the compound of formula (I) is a compound of the formula (Ia):



(Ia)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:

R^3 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester; and

R^4 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester;

X^1 is alkyl or alkenyl;

X^2 is N or CR^5, wherein R^5 is absent, hydrogen, alkyl or aryl.

[00143] Embodiment 3 relates to the compound of Embodiment 1, wherein the compound of formula (I) is a compound of the formula (Ib):



(Ib)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[00144] Embodiment 4 relates to the compound of Embodiment 1, wherein the compound of formula (I) is a compound of the formulae (Ic) and (Id):



and



(Ic) (Id)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

n is 0, 1 or 2.

[00145] Embodiment 5 relates to the compound of Embodiment 1, wherein the compound of formula (I) is a compound of the formulae (Ie) and (If):



and



(Ie) (If)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

q is 0, 1 or 2.

[00146] Embodiment 6 relates to the compound of Embodiment 1, wherein the compound of formula (I) is a compound of the formula (Ig):



(Ig)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl;

each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl;

X^1 is alkyl or alkenyl; and

X^2 is N or CR^5, wherein R^5 is absent, hydrogen, alkyl or aryl.

[00147] Embodiment 7 relates to the compound of Embodiment 6, wherein at least one of R^6 is R^7-C=O or R^8-C=O, wherein R^8 is halo.

[00148] Embodiment 8 relates to the compound of Embodiments 6-7, wherein X^1 is $-(CH_2)_n-$, wherein n is 0, 1 or 2.

[00149] Embodiment 9 relates to the compound of Embodiment 1, wherein the compound of formula (I) is a compound of the formulae (Ih) and (Ii):



(Ih)



(Ii)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

n is 0, 1 or 2;

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl; and

each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl.

[00150] Embodiment 10 relates to the compound of Embodiment 9, wherein at least one of R^6 is R^7-C=O or R^8-C=O, wherein R^8 is halo.

[00151] Embodiment 11 relates to the compound of Embodiments 1-10, wherein the compound of formula (I) is a compound of the formula:



,



,



, or

pharmaceutically acceptable salts, polymorphs, prodrugs, solvates or clathrates thereof.

[00152] Embodiment 12 relates to the compound of the formula (II):



(II)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl;

X^1 is alkyl or alkenyl;

X^2 is N or CR^5, wherein R^5 is absent, hydrogen, alkyl or aryl; and

X^3 NR^8 or $C(R^8)_2$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl.

[00153] Embodiment 13 relates to the compound of Embodiment 12, wherein X^1 is $-(CH_2)_n-$, wherein n is 0, 1 or 2.

[00154] Embodiment 14 relates to the compound of Embodiments 12-13, wherein R^6 is R^7-C=O or R^8-C=O, wherein R^8 is halo.

[00155] Embodiment 15 relates to the compound of Embodiments 12-14, wherein the compound of formula (II) is a compound of the formula:



and

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl.

[00156] Embodiment 16 relates to the compound of Embodiment 15, wherein at least one of R^6 is R^7-C=O or R^8-C=O, wherein R^8 is halo.

[00157] Embodiment 17 relates to the compound of Embodiments 15-16, wherein at least one of R^6 is F or CF_3.

[00158] Embodiment 18 relates to the compound of the formula (III):



(III)

wherein:

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

Y^2 is alkyl, NR^8 or O;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted; and

R^{10}-hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl or $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9, $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted.

[00159] Embodiment 19 relates to the compound of Embodiment 18, wherein R^9-Y^1 forms the same group or a different group as R^{10}-Y^2.

[00160] Embodiment 20 relates to the compound of Embodiments 18-19 wherein Y^1 is O or NR^8, wherein R^8 can be alkyl or cycloalkyl.

[00161] Embodiment 21 relates to the compound of Embodiment 18, wherein Y^1 or Y^2 is CH_2.

[00162] Embodiment 22 relates to the compound of Embodiments 18-21, wherein R^9-Y^1 forms different groups than R^{10}-Y^2.

[00163] Embodiment 23 relates to the compound of Embodiments 18-22, wherein the compound is a compound of the formula:


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



wherein:

each of the foregoing compounds can be further substituted;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl, alkoxy or heterocyclyl; and Het^1 and Het^2 are each, independently, a heterocyclyl group.

[00164] Embodiment 24 relates to the compound of Embodiment 23, wherein Het^1 and Het^2 are each, independently, furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridinyl or pyrimidinyl.

[00165] Embodiment 25 relates to the compound of the formula (IV):



(IV)

wherein:

X^4 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

X^5 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each R^{13} is independently H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl;

R^{14} is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl, thioacyl, $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{15} is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl, thioacyl, $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl,

acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or

R^{13} and R^{14}, together with the atoms to which they are each attached, form a heterocyclyl group.

[00166] Embodiment 26 relates to the compound of Embodiment 25, wherein R^{14} or R^{15} is $R^{14}C(S)$.

[00167] Embodiment 27 relates to the compound of Embodiments 25-26, wherein R^{14} forms a different group than R^{15}.

[00168] Embodiment 28 relates to the compound of Embodiment 25-27, wherein at least one of R^{14} and R^{15} can be acyl, each of which can be substituted with a group R^9-Y^1-, wherein:

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen, aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.

[00169] Embodiment 29 relates to the compound of Embodiments 25-28, wherein the compound is a compound of the formula:


,

,

,

,

or


or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[00170] Embodiment 30 relates to the compound of Embodiments 25-29, wherein the compound is a compound of the formula:







or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[00171] Embodiment 31 relates to the compound of Embodiments 25-29, wherein the compound is a compound of the formula:













,

,

,

,

,

,

,

,

,

,

,

,

,

,

5


,

,

,

, and


or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen, aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl, alkoxy or heterocyclyl; and

Het^1 and Het^2 are each, independently, a heterocyclyl group.

[00172] Embodiment 32 relates to the compound of Embodiment 31, wherein the compound is a compound of the formula:


,


, and


or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[00173] Embodiment 33 relates to the compound of Embodiment 25, wherein the compound is a compound of the formula:


,


,


,


,


,


,


,


,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

, and


or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen, aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl, alkoxy or heterocyclyl; and

Het^1 and Het^2 are each, independently, a heterocyclyl group.

[00174] Embodiment 34 relates to the compound of Embodiment 33, wherein the compound is a compound of the formula





,



, and



or

a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[00175] Embodiment 35 relates to the compound of Embodiment 25, wherein the compound is a compound of the formula:



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



5



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen, aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl, alkoxy or heterocyclyl; and Het^1 and Het^2 are each, independently, a heterocyclyl group.

[00176] Embodiment 36 relates to the compound of the formula (V):



(V)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

X^1 is alkyl or alkenyl;

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl;

R^{14} is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

R^{15} is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{16} is H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl; or

R^{14} and R^{15} or R^{15} and R^{16}, together with the atoms to which they are each attached, form a cyclic group.

[00177] Embodiment 37 relates to the compound of Embodiment 36, wherein R^{14} and R^{15} or R^{15} and R^{16}, together with the atoms to which they are each attached, form a cycloalkyl or a heterocyclyl group.

[00178] Embodiment 38 relates to the compound of Embodiments 36-37 wherein X^1 is $-(CH_2)_n-$, wherein n is 0, 1 or 2.

[00179] Embodiment 39 relates to the compound of Embodiments 36-38, wherein at least one of R^{14} and R^{15} is halogenated aryl.

[00180] Embodiment 40 relates to the compound of Embodiments 36-39, wherein the halogenated aryl is a para-halogenated aryl.

[00181] Embodiment 41 relates to the compound of Embodiments 36-40, wherein the para-halogenated aryl is a para-fluoro aryl group.

[00182] Embodiment 42 relates to the compound of Embodiment 36, wherein the compound is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[00183] Embodiment 43 relates to the compound of Embodiments 36-42, wherein R^{16} is $C(O)R^8$.

[00184] Embodiment 44 relates to the compound of Embodiment 36, wherein the compound is a compound of the formula:



or

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[00185] Embodiment 45 relates to the compound of the formula (VI):



(VI)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

X^1 is alkyl or alkenyl;

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl;

each R^{13} is H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl;

R^{17} is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

R^{18} is hydrogen, alkyl, OR^{19} (wherein R^{19} is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl) cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or

R^{17} and R^{18}, together with the atoms to which they are attached, form a cycloalkyl, aryl or heterocyclyl group. In one example, OR^{19} forms a heteroaryl group of the formula:



; or

R^{13} and R^{18}, together with the atoms to which they are each attached, form a heterocyclyl group.

[00186] Embodiment 46 relates to the compound of Embodiment 45, wherein X^1 is $-(CH_2)_n-$, wherein n is 0, 1 or 2.

[00187] Embodiment 47 relates to the compound of Embodiments 45-46, wherein R^{18} is $C(O)R^8$.

[00188] Embodiment 48 relates to the compound of Embodiment 45, wherein the compound is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[00189] Embodiment 49 relates to the compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

X^4 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

X^5 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each R^{13} is independently H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl;

R^{14} is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl, thioacyl, $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{15} and R^{16} are each, independently, hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl, thioacyl, $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or

R^{13} and R^{14}, together with the atoms to which they are each attached, form a heterocyclyl group; or

R^{13} and R^{16}, together with the atoms to which they are each attached, form a cycloalkyl, heterocyclyl or aryl group.

[00190] Embodiment 50 relates to the compound of Embodiment 49, wherein the compound is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

[00191] Embodiment 51 relates to a pharmaceutical composition comprising one or more compounds of Embodiments 1-50 and one or more pharmaceutically acceptable excipients.

[00192] Embodiment 52 relates to a method for treating a neurodegenerative disease comprising administering a therapeutically effective amount of fluspriline, at least one compound of Embodiments 1-50 or a pharmaceutical composition of Emdoiment 51 to a subject in need thereof.

[00193] Embodiment 53 relates to the method of Embodiment 52, wherein the neurodegenerative disease is at least one of Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS.

[00194] Embodiment 54 relates to a method for reducing, substantially eliminating or eliminating dysregulation of proteostasis comprising administering a therapeutically effective amount of fluspriline, at least one compound of Embodiments 1-50 or a pharmaceutical composition of Embodiment 51 to a subject in need thereof.

[00195] Embodiment 55 relates to a method for reducing, substantially eliminating or eliminating the accumulation of intrinsically disordered proteins comprising administering a therapeutically effective amount of fluspriline, at least one compound of Embodiments 1-50 or a pharmaceutical composition of Embodiment 51 to a subject in need thereof..

What is Claimed:

1. A compound of the formula (I):



(I)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:

R^1 is alkyl, alkenyl, cycloalkyl, aryl or heteroaryl; and

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl.

2. The compound of claim 1, wherein the compound of formula (I) is a compound of the formula (Ia):



(Ia)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:

R^3 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester; and

R^4 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or ester;

X^1 is alkyl or alkenyl;

X^2 is N or CR^5, wherein R^5 is absent, hydrogen, alkyl or aryl.

3. The compound of claim 1, wherein the compound of formula (I) is a compound of the formula (Ib):



(Ib)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

4. The compound of claim 1, wherein the compound of formula (I) is a compound of the formulae (Ic) and (Id):



and



(Ic) (Id)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

n is 0, 1 or 2.

5. The compound of claim 1, wherein the compound of formula (I) is a compound of the formulae (Ie) and (If):



and



(Ie) (If)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

q is 0, 1 or 2.

6. The compound of claim 1, wherein the compound of formula (I) is a compound of the formula (Ig):



(Ig)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl;

each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl;

X^1 is alkyl or alkenyl; and

X^2 is N or CR^5, wherein R^5 is absent, hydrogen, alkyl or aryl.

7. The compound of claim 6, wherein at least one of R^6 is R^7-C=O or R^8-C=O, wherein R^8 is halo.

8. The compound of claim 6, wherein X^1 is $-(CH_2)_n-$, wherein n is 0, 1 or 2.

9. The compound of claim 1, wherein the compound of formula (I) is a compound of the formulae (Ih) and (Ii):



(Ih)



(Ii)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

n is 0, 1 or 2;

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl; and

each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl.

10. The compound of claim 9, wherein at least one of R^6 is R^7-C=O or R^8-C=O, wherein R^8 is halo.

11. The compound of claim 1, wherein the compound of formula (I) is a compound of the formula:


,

,

, or

pharmaceutically acceptable salts, polymorphs, prodrugs, solvates or clathrates thereof.

12. A compound of the formula (II):



(II)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl;

X^1 is alkyl or alkenyl;

X^2 is N or CR^5, wherein R^5 is absent, hydrogen, alkyl or aryl; and

X^3 NR^8 or $C(R^8)_2$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl.

13. The compound of claim 12, wherein X^1 is $-(CH_2)_n-$, wherein n is 0, 1 or 2.

14. The compound of claim 12, wherein R^6 is R^7-C=O or R^8-C=O, wherein R^8 is halo.

15. The compound of claim 12, wherein the compound of formula (II) is a compound of the formula:





and

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein each R^6 is independently H, alkyl, halo, SR^7 (wherein each R^7 is H, alkyl, aryl, acyl or heterocyclyl), amino, OR^7, or acyl.

16. The compound of claim 15, wherein at least one of R^6 is R^7-C=O or R^8-C=O, wherein R^8 is halo.

17. The compound of claim 15, wherein at least one of R^6 is F or CF_3.

18. A compound of the formula (III):



(III)

wherein:

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

Y^2 is alkyl, NR^8 or O;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted; and

R^{10} hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl or $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9, $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted.

19. The compound of claim 18, wherein R^9-Y^1 forms the same group or a different group as R^{10}-Y^2.

20. The compound of claim 18, wherein Y^1 is O or NR^8, wherein R^8 can be alkyl or cycloalkyl.

21. The compound of claim 18, wherein Y^1 or Y^2 is CH_2.

22. The compound of claim 18, wherein R^9-Y^1 forms different groups than R^{10}-Y^2.

23. The compound of claim 18, wherein the compound is a compound of the formula:



,



,



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,



wherein:

each of the foregoing compounds can be further substituted;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl, alkoxy or heterocyclyl; and Het^1 and Het^2 are each, independently, a heterocyclyl group.

24. The compound of claim 23, wherein Het^1 and Het^2 are each, independently, furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridinyl or pyrimidinyl.

25. A compound of the formula (IV):



(IV)

wherein:

X^4 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

X^5 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each R^{13} is independently H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl;

R^{14} is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl, thioacyl, $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{15} is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl, thioacyl, $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or

R^{13} and R^{14}, together with the atoms to which they are each attached, form a heterocyclyl group.

26. The compound of claim 25, wherein R^{14} or R^{15} is $R^{14}C(S)$.

27. The compound of claim 25, wherein R^{14} forms a different group than R^{15}.

28. The compound of claim 25, wherein at least one of R^{14} and R^{15} can be acyl, each of which can be substituted with a group R^9-Y^1-, wherein:

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen, aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.

29. The compound of claim 25, wherein the compound is a compound of the formula:  ,  ,  ,  ,  or 

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

30. The compound of claim 25, wherein the compound is a compound of the formula:

 ,  ,  ,  ,or 

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

31. The compound of claim 25, wherein the compound is a compound of the formula:

 ,  ,  ,  ,  , 



,



,



,



,



,



,



,



,



,



,

5

,

,


,

,

,

,

,

,

,

,

,

,

,

, and


or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen, aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl, alkoxy or heterocyclyl; and Het^1 and Het^2 are each, independently, a heterocyclyl group.

32. The compound of claim 31, wherein the compound is a compound of the formula:



,



, and



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

33. The compound of claim 25, wherein the compound is a compound of the formula:



,



,



,



,



,



,


,

,

,

,

,

,

,

,

5
,

,

,



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen, aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl, alkoxy or heterocyclyl; and Het^1 and Het^2 are each, independently, a heterocyclyl group.

34. The compound of claim 33, wherein the compound is a compound of the formula





,



, and



or

a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

35. The compound of claim 25, wherein the compound is a compound of the formula:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



















or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein:

each of the foregoing compounds can be further substituted;

Y^1 is alkyl, NR^8 or O, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^9 is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, $CH(R^9)_2$, CH_2R^9, OR^9, NHR^9 or $S(O)_xR^9$, wherein each alkyl, cycloalkyl, aryl, heteroaryl is optionally substituted with, e.g., groups including halogen, aryl, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

W is N or C-R^{9A}; X is N or C-R^{9A}; Y is N or C-R^{9A}; and Z is N or C-R^{9A}; wherein each R^{9A} is independently H, halo, alkyl, haloalkyl, alkoxy or heterocyclyl; and

Het^1 and Het^2 are each, independently, a heterocyclyl group.

36. A compound of the formula (V):



(V)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

X^1 is alkyl or alkenyl;

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl;

R^{14} is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

R^{15} is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{16} is H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl; or

R^{14} and R^{15} or R^{15} and R^{16}, together with the atoms to which they are each attached, form a cyclic group.

37. The compound of claim 36, wherein R^{14} and R^{15} or R^{15} and R^{16}, together with the atoms to which they are each attached, form a cycloalkyl or a heterocyclyl group.

38. The compound of claim 36, wherein X^1 is $-(CH_2)_n-$, wherein n is 0, 1 or 2.

39. The compound of claim 36, wherein at least one of R^{14} and R^{15} is halogenated aryl.

40. The compound of claim 36, wherein the halogenated aryl is a para-halogenated aryl.

41. The compound of claim 40, wherein the para-halogenated aryl is a para-fluoro aryl group.

42. The compound of claim 36, wherein the compound is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

43. The compound of claim 36, wherein R^{16} is $C(O)R^8$.

44. The compound of claim 36, wherein the compound is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

45. A compound of the formula (VI):



(VI)

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

X^1 is alkyl or alkenyl;

R^2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl;

each R^{13} is H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl;

R^{17} is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;

R^{18} is hydrogen, alkyl, OR^{19} (wherein R^{19} is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl) cycloalkyl, aryl, heteroaryl, acyl, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or

R^{17} and R^{18}, together with the atoms to which they are attached, form a cycloalkyl, aryl or heterocyclyl group. In one example, OR^{19} forms a heteroaryl group of the formula:



; or

R^{13} and R^{18}, together with the atoms to which they are each attached, form a heterocyclyl group.

46. The compound of claim 45, wherein X^1 is $-(CH_2)_n-$, wherein n is 0, 1 or 2.

47. The compound of claim 45, wherein R^{18} is $C(O)R^8$.

48. The compound of claim 45, wherein the compound is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

49. A compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof,

wherein:

X^4 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

X^5 is CR^8 or N, wherein R^8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each R^{13} is independently H, acyl, carboxyl or $C(O)R^8$, wherein R^8 is H, alkyl, acyl, aryl, benzyl or heterocyclyl;

R^{14} is hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl, thioacyl, $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and

R^{15} and R^{16} are each, independently, hydrogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, acyl, thioacyl, $R^{14}C(NR^{14})$, amido or carbamate, each of which alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido, and carbamate is optionally substituted with cycloalkyl, aryl, heteroaryl, each of which cycloalkyl, aryl, and heteroaryl is optionally substituted with halogen, amino, alkoxy, $S(O)_x$, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or

R^{13} and R^{14}, together with the atoms to which they are each attached, form a heterocyclyl group; or

R^{13} and R^{16}, together with the atoms to which they are each attached, form a cycloalkyl, heterocyclyl or aryl group.

50. The compound of claim 49, wherein the compound is a compound of the formula:



or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.

51. A pharmaceutical composition comprising at least one of fluspirilene and one or more compounds of claims 1, 12, 18, 25, 36, 45 or 49 and one or more pharmaceutically acceptable excipients.

52. A method for treating a neurodegenerative disease comprising administering a therapeutically effective amount of at least one of fluspirilene and one or

more compounds of claims 1, 12, 18, 25, 36, 45 or 49 to a subject in need thereof.

53. The method of claim 52, wherein the neurodegenerative disease is at least one of Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS.

54. A method for reducing, substantially eliminating or eliminating dysregulation of proteostasis comprising administering a therapeutically effective amount of at least one of fluspirilene and one or more compounds of claims 1, 12, 18, 25, 36, 45 or 49 to a subject in need thereof.

55. A method for reducing, substantially eliminating or eliminating the accumulation of intrinsically disordered proteins comprising administering a therapeutically effective amount at least one of fluspirilene and one or more compounds of claims 1, 12, 18, 25, 36, 45 or 49 to a subject in need thereof.

56. The method of claim 55, wherein the intrinsically disordered proteins comprise α-syn.

57. A method for treating a neurodegenerative disease comprising administering a composition of claim 51 to a subject in need thereof.

58. The method of claim 57, wherein the neurodegenerative disease is at least one of Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS.

59. A method for reducing, substantially eliminating or eliminating dysregulation of proteostasis comprising administering a composition of claim 51 to a subject in need thereof.

60. A method for reducing, substantially eliminating or eliminating the accumulation of intrinsically disordered proteins comprising administering a composition of claim 51 to a subject in need thereof.

61. The method of claim 60, wherein the intrinsically disordered proteins comprise α-syn.



FIG. 1A

Catalytic Site	3 Sites	CT-L	T-L	Casp-L
Substrate	Combo	Suc-LLVY -AMC	Boc-LRR -AMC	Z-LLE -AMC
AC_{200} (μM)	2.2 ± 0.2	1.0 ± 0.3	10.9 ± 3.0	2.2 ± 0.3
Max Fold Increase	9.8 ± 0.5	12.9 ± 2.2	17.7 ± 5.3	16.3 ± 2.3

FIG. 1B



FIG. 2A



FIG. 2B



FIG. 3



FIG. 4A



FIG. 4B



FIG. 4C



FIG. 4D



FIG. 5A

Substrate	AC_{200} (μM)	Max Fold Increase
3 Sites	1.9 ± 0.5	20.8 ± 2.3
CT-L	4.7 ± 1.6	15.0 ± 6.9
T-L	5.6 ± 0.8	30.6 ± 7.4
Casp-L	4.1 ± 0.6	36.8 ± 12.2

FIG. 5B



FIG. 6A


150
100
50
0
% α-syn Remaining (Rel. Ctrl)
***
***
*
Vehicle
Flu. 1 μM
Flu. 3 μM
Flu. 10 μM

FIG. 6B


150
100
50
0
% α-syn Remaining (Rel. Ctrl)
****
****
**
Vehicle
N-acyl Flu. 1 μM
N-acyl Flu. 3 μM
N-acyl Flu. 10 μM

FIG. 6C


Fluspirilene
Amc Hydrolysis by 20S
(% of Control)
200
150
100
50
0
****
****
****
**
ns
Vehicle
Vehicle + α-syn
1 μM
3 μM
5 μM
10 μM

FIG. 7A


N-acylated Fluspirilene
Amc Hydrolysis by 20S
(% of Control)
200
150
100
50
0
****
****
****
****
*
Vehicle
Vehicle + α-syn
1 μM
3 μM
5 μM
10 μM

FIG. 7B


Fluspirilene
Amc Hydrolysis by 20S
(% of Control)
200
150
100
50
0
***
****
**
ns
ns
Vehicle
Vehicle + Abeta
1 µM
3 µM
5 µM
10 µM

FIG. 7C


N-acylated Fluspirilene
Amc Hydrolysis by 20S
(% of Control)
200
150
100
50
0
*
***
*
ns
ns
Vehicle
Vehicle + Abeta
1 µM
3 µM
5 µM
10 µM

FIG. 7D



20S	-	+	+	+	+	+
α-synuclein	+	+	+	+	+	+
Fluspirilene (μM)	-	-	1	3	10	-
BTZ (μM)	-	-	-	-	-	10

FIG. 7E



FIG. 7F



20S	-	+	+	+	+	+
α-synuclein	+	+	+	+	+	+
N-acylated Fluspirilene (μM)	-	-	1	3	10	-
BTZ (μM)	-	-	-	-	-	10

FIG. 7G



FIG. 7H



A53T α-synuclein Remaining (Relative to Vehicle)	0	1.0	1.2	0.2	0.9	0.2	0.9
A53T α-synuclein Remaining (Percent Relative to Vehicle)	0	100	119	20	96	22	94

FIG. 8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 21/45446

A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61K 31/445; C07D 471/10; A61P 25/00 (2021.01)

CPC - A61K 31/445; C07D 471/10; A61P 25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2020/021378 A1 (MARIA CECILIA HOSPITAL S.P.A.) 30 January 2020 (30.01.2020) pg 20, ln 5-8, compound 13; pg 22, ln 5-9	1, 51/1
A	US 2007/0299072 A1 (JANUSZ et al.) 27 December 2007 (27.12.2007) para [0002], [0253]-[0254], Table II, Entry 1	1, 51/1
A	US 6,482,829 B2 (GALLEY et al.) 19 November 2002 (19.11.2002) col 3, ln 28-47; col 27, ln 22-40	1, 51/1
A	CN 101838269 A (INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY OF AMMS) 22 September 2010 (22.09.2010) translation, pg 8, para 16 to pg 9, para 1; pg 11, para 2-para 3, compound 412	1, 51/1

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"D" document cited by the applicant in the international application
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 October 2021	JAN 10 2022
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450. Facsimile No. 571-273-8300	Authorized officer Kari Rodriquez Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 21/45446

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
--Please see attached sheet----

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1 and 51/1

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 21/45446

Attachment to Box.No.III:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+: Claims 1-51, directed to a compound of the Formula I, or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, as described in claim 1, further represented by Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) or (Ii), and selected from the compounds specified in claim 11; a compound of the formula specified in claim 13; a compound of Formula II or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, selected from the compounds specified in claim 15; a compound according to Formula (III), or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof further represented by the formulae specified in claim 23; a compound of (IV), or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, selected from the compounds specified in claims 34; a compound of formula (V) or (VI), or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof; and to a compound of the formula specified in claim 49, further represented by the formula specified in claim 50, or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, and a pharmaceutical composition comprising said compound.
The compound and composition will be searched to the extent that the compound encompasses the first species of claim 1, represented by Formula I, or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof wherein R1 is C1-alkyl; and R2 is hydrogen.
It is believed that claims 1 and 51/1 read on this first named invention, and thus these claims will be searched without fee to the extent that they encompass the first species of claim 1, described above.
Applicant is invited to elect additional compound(s) wherein each additional compound elected will require one additional invention fee. Applicants must specify the claims that encompass any additionally elected compound. Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the '+' group(s) will result in only the first claimed invention to be searched. Additionally, an exemplary election wherein different actual variables are selected is suggested. An exemplary election would be the first -listed compound of claim 11, represented by Formula (I) and (Ia), wherein
R2 is aryl, which is unsubstituted phenyl; X1 is C3-alkyl; X2 is CR5;
R5 is H; and R3 and R4 are each aryl, which is unsubstituted phenyl (i.e., claims 1-2, 4, 6, 8-9, 11 and 51/1).

Group II: Claims 52-61, directed to a method for treating a neurodegenerative disease and to a method for reducing, substantially eliminating or eliminating dysregulation of proteostasis or reducing, substantially eliminating or eliminating the accumulation of intrinsically disordered proteins, comprising administering a therapeutically effective amount of at least one of fluspirilene and one or more compounds of Formula (I), (II),, (III), (IV), (V) or (VI), or a composition comprising said compound, to a subject in need thereof.

The group of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I+ includes the technical feature of a unique compound, which is not required by any other invention of Group I+.

Group II includes the technical feature of a method for treating a neurodegenerative disease or a method for reducing, substantially eliminating or eliminating dysregulation of proteostasis in a subject, not required by Group I+.

Common technical features:

The inventions of Group I+ share the technical features of a compound according to Formula (I), (II), (III), (IV), (V) or (VI), or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof; and a pharmaceutical composition comprising said compound.

Groups I+ and II also share the technical features of a compound according to Formula (I), (II), (III), (IV), (V) or (VI), or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof; and a pharmaceutical composition comprising said compound.

These shared technical features, however, do not provide a contribution over the prior art, as being anticipated by WO 2020/021378 A1 to Maria Cecilia Hospital S.P.A. published on 30 January 2020 (hereinafter MCH), which discloses a compound according to Formula (I), wherein R1 is C1-alkyl, which is unsubstituted and R2 is aryl, which is unsubstituted phenyl (pg 20, ln 5-8, compound 13) and further teachers a pharmaceutical composition comprising said compound (pg 22, ln 5-9).

As said compound and composition were known in the art at the time of the invention, these cannot be considered special technical features, that would otherwise unify the inventions of Group I+ or those of Groups I+-II.

The inventions of Groups I+-II, thus lack unity under PCT Rule 13.